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Fungal infections caused by Candida species, particularly C. albicans and C. 
glabrata, have become a serious threat to public health. The rising drug resistance has 
prevented effective treatment and increased the mortal rate. Novel approaches to 
improve the therapeutic effects of antifungal agents and allow delivery of agents that 
are not normally cell-permeable are in demand.  
In order to improve the intracellular delivery of antifungal agents, we have 
investigated using cell-penetrating peptides as drug carriers for treating fungal 
infections. CPPs have been widely studied as tools for delivering a variety of molecular 
cargo into cells, including DNA, RNA, proteins, and nanoparticles. Previous work with 
CPPs has mainly focused on their uptake in mammalian cells, but CPPs also have 
potential as drug delivery and research tools in other organisms, including Candida 
pathogens.  
We have explored various well-studied CPPs to identify peptides that retain their 
translocation capability with Candida cells, including pVEC, penetratin, MAP, MPG, 
  
SynB, TP-10 and cecropin B. The CPPs pVEC, penetratin, MAP and cecropin B show 
a higher level in the cytosol adopt direct translocation mechanisms and exhibit toxicity 
towards C. albicans. Our peptide localization and mechanistic studies allow better 
understanding of the mode of translocation for different CPPs, which is related to the 
potential toxicity towards Candida pathogens. 
To further understand the molecular mechanisms of translocation of CPP, we 
investigated the biophysical properties of the peptides. CPPs that previously were 
shown to use direct translocation mechanisms (pVEC, MAP, and cecropin B) exhibit 
helical conformations upon interaction with cells due to the hydrophobic interaction 
with the core of bilayers. Membrane associations of peptides that entered cells via 
endocytosis were controlled by electrostatic forces. Our novel structure 
characterization methods using circular dichroism with live fungal cells, along with 
Monte Carlo simulations, allow us to understand how CPPs interact with cell 
membranes and how the membrane association affects the translocation mechanisms.  
After beginning to understand the structure-function relationships of CPPs, we 
engineered two CPPs, pVEC and SynB, to enable better translocation efficacy and 
manipulation of translocation mechanisms. We tuned the properties of the peptides, 
including the net charge and the hydrophobicity, to alter intracellular fates and the level 
of antifungal activity. These results are promising and motivate better peptide 
engineering for specific purposes.   
Our work with CPPs and fungal pathogens contributes to the understanding of 
structure-function relationship of CPPs in Candida species. We have provided the 
foundation for further peptide engineering and explorations into applications of CPPs 
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Chapter 1. Introduction 
Yeast infections can be caused by Candida species and other fungal species, 
and the most common clinically isolated strains are C. albicans and C. glabrata [1]. 
These fungi can develop drug resistance to traditional antifungal agents rapidly [2, 3]. 
The Centers for Disease Control and Prevention (CDC) has listed fluconazole-
resistant Candida species as a “serious threat” to public health and estimated an 
increased healthcare cost of $6000-$9000 per infection case [4]. Although these 
fungal infections can currently still be treated, the drug resistance can be problematic 
as it can delay the initial diagnosis of infection and the administration of an effective 
drug [5].  
Opportunistic Candida species can be isolated from the human digestive tract 
and other mucosal surfaces, such as the oral cavity. They typically do not initiate 
infections or symptoms. However, for patients with suppressed immune systems, 
such as people with AIDS or those undergoing chemotherapy, fungi can cause serious 
systemic infections, which are hard to treat and have a high mortality rate. Treating 
fungal infections is a growing concern due to the limited drug targets and the rapidly 
rising drug resistance to the traditional antifungal agents, which motivates research 
into novel therapeutic methods or drug delivery vehicles to improve the efficacy of 
antifungal agents.  
1.1. Candida species and traditional antifungal agents 
Currently, the first-line treatment for fungal infections includes antifungal 
drugs such as polyenes and azoles [6]. The most commonly used polyenes drugs are 
 
2 
amphotericin B (Figure 1.1A) formulations. Amphotericin B is an effective antifungal 
agent for treating infections caused by C. albicans, yet it has reduced activity towards 
C. glabrata. Amphotericin B binds to the ergosterol in the cell membrane of fungi, 
causing pore formation and cell leakage, leading to cell death [7]. Although drug 
resistance of amphotericin B is rarely reported, the drug has severe side effects such 
as high fever, shaking chills, and even organ damage including kidney damage [8]. 
Azole drugs, including fluconazole (Figure 1.1A) and itraconazole, are also 








Figure 1.1 Example of antifungal drugs that commonly used for treating fungal infections caused 
by C. albicans. (A) Amphotericin B, polyene drug. (B) Fluconazole, azole drug. 
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involves inhibition of ergosterol synthesis [9]. They inhibit the activity of a 
cytochrome P450 enzyme, 14-α-demethylase, the intracellular enzyme that converts 
lanosterol to ergosterol and affect membrane integrity. Azole drugs are mostly 
effective towards C. albicans, but not towards C. glabrata due to the differences in 
membrane enzyme compositions [10]. Even for C. albicans, cells can develop 
resistance to azoles through multiple mechanisms, including Erg3p inactivation and 
activation of major facilitator superfamily transporters (MFS) [9].  Although the 
toxicity of azoles to patients is not as significant as for amphotericin B, the rapid 
development of drug resistance still makes azole treatment less effective.  
Although amphotericin B, azoles, and other drugs are effective antifungal 
agents, the severe side effects and rising drug resistance demand novel therapeutic 
methods. As treatment with these traditional drugs continue, C. albicans and other 
fungal pathogens will evolve more mechanisms to reduce the therapeutic effects, 
leading to an increased number of drug-resistant infections, delaying the treatment 
and causing a higher mortality rate. Thus the discovery of novel drugs or drug 
delivery approaches is becoming more essential to prevent rising drug resistance.  
1.2. Application of cell-penetrating peptides (CPPs) 
One potential new therapeutic method is to use cell-penetrating peptides 
(CPPs) as a novel drug delivery vehicle. CPPs are small peptides, approximately 30 
amino acids [11, 12] or fewer, with the capability to cross cellular membranes. These 
short peptides are often positively charged with several lysine or arginine residues in 
the sequence. The polar/charged residues and the non-polar/hydrophobic residues are 
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commonly arranged in an alternating pattern that leads to an amphipathic secondary 
structure [12].  
The first CPP, the Tat peptide, was discovered from the HIV virus in 1988 
[11]. Tat is the trans-activating transcriptional activator of the virus, which assists in 
uptake of the virus by mammalian cells in culture. Over three decades of research, 
more than 100 CPPs have been discovered or synthesized [12]. Studying  natural 
peptides allows exploration of the highly varied structures of CPPs. De novo 
synthesized peptides such as MAP and (KFF)3K, can be designed to have a highly 
organized amphipathic structure and show significant translocation efficacy [13, 14], 
which enables a better understanding of CPPs.  
CPPs can carry molecular cargos as they cross into the cytosol. They have 
been exploited to deliver various biomolecular cargos into cells, including DNA [15-
19], siRNA [20, 21], and nanoparticles [22]. More importantly, CPPs are widely used 
for delivering proteins into mammalian cells including insulin [23], green fluorescent 
protein (GFP) [24], β-galactosidase [25], and antibody fragments [26].  
1.3. Limited use of CPPs with fungal pathogens 
Although CPPs show promise for applications in cargo delivery and cell 
recognition, limitations exist in their development for therapeutic applications, 
especially for applications that target fungal pathogens. Most CPPs were discovered 
or screened in mammalian cells. The translocation process is better understood in 
mammalian cells, with limited information about the translocation toward other types 
of cells, such as bacterial and fungal cells [27-32]. In order to utilize CPPs for 
enhanced drug delivery to combat fungal infection, a more detailed study of CPP 
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translocation in fungal cells is needed to identify the peptides that can be used in 
fungi.  
In addition, although CPPs have been widely used with mammalian cells, a 
clear explanation of their translocation mechanisms is often still lacking. Several 
mechanisms have been proposed to explain the translocation in mammalian cells, but 
no comprehensive mechanistic study of cellular uptake has been done in fungal cells. 
In order to use CPPs in fungal cells, or further engineer CPPs for fungi-specific cargo 
delivery, a more detailed mechanistic study is needed.  
1.4. Overview of dissertation 
This dissertation describes my work to understand CPPs and cargo delivery in 
fungal cells, as well as to engineer CPPs for enhanced translocation and cell-specific 
cargo delivery. In Chapter 2, I review relevant literature of CPPs and their 
mechanisms of action. I also explore the limitation of applying CPPs for drug 
delivery and the opportunities of studying CPPs in Candida species. In Chapter 3, I 
present a screening study of CPPs in fungal cells. Subcellular localization of several 
well-studied CPPs was carefully analyzed to reveal the trafficking of the peptides 
Chapter 4 expands on the work in Chapter 3. It provides biophysical information 
about CPP structure and how it affects the interaction between CPPs and fungal cells. 
In Chapter 5, I present my study on cargo delivery into C. albicans using CPPs. Using 
direct genetic fusion of CPPs to cargo and recombinant expression, I was able to 
produce CPP-green fluorescent protein (GFP) fusion proteins with the capability for 
intracellular translocation. In Chapter 6, I present my preliminary data on CPP 
engineering. I modified biophysical properties of CPPs to understand the structure-
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function relationship of CPPs. Finally, Chapter 7 describes several possible future 
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Chapter 2. Cell-penetrating peptides 
CPPs, also known known as protein translocation domain (PTD) or Trojan 
horse peptides, can transport biomolecules with various sizes and properties. 
Compared with other drug delivery vehicles such as virus vectors, CPPs are less toxic 
to host cells and can be easily engineered or designed for specific purposes [1-3]. I 
review the structures, properties, translocation mechanisms, and potential applications 
of CPPs in this chapter.  
2.1. Classes of CPPs 
Currently no unified method exists to classify CPPs. They can be categorized 
by either their origins or their properties. Based on their origin, there are three major 
types of CPPs: (1) protein-derived peptides, such as penetratin, Tat, and pVEC, which 
came from natural proteins; (2) model peptides, which are de novo designed, like 
MAP and (Arg)8; and (3) chimeric peptides, such as MPG, Pep-1, and transportan that 
include multiple regions from different origins, which help the peptides to enter cells 
and achieve specific subcellular localization [1].  
Another way to categorize CPPs is based on their structural and functional 
characteristics: (1) cationic peptides, (2) hydrophobic peptides, (3) amphipathic 
peptides, and (4) antimicrobial peptides [3]. Some peptides may belong to more than 
one category. Example of CPPs in all chapters are listed in Table 2.1 and defined by 
their origin or structural or functional characteristics. The structural classes of CPPs 









MTS AAVALLPAVLLALLAP Hydrophobic 





VTVLALGALAGVGV Hydrophobic Integrin β3 (natural peptide) [5] 




CyLoP CRWRWKCCKK Cationic Crotamine (protein-derived) [7] 




Cationic Mastoparan (protein-derived) [9] 
TP-10 AGYLLGKINLKALAALAKKIL Cationic Transportan (protein-derived) [10] 
SynB RGGRLSYSRRRFSTSTGR Cationic Protegrin (protein-derived) [11] 
R9F2 RRRRRRRRRFF Cationic Model [12] 












Amphipathic Chimeric [16] 
YTA 2 YTAIAWVKAFIRKLRK Amphipathic Model [17] 
YTA 4 IAWVKAFIRKLRKGPLG Amphipathic Model [17] 




Amphipathic Model [19] 
MAP KLALKLALKALKAALKLA Amphipathic Model [19] 
pVEC LLIILRRRIRKQAHAHSK Amphipathic 


















Amp Hemolymph (protein-derived) [23] 











Amp Saliva (natural peptide) [26] 
Buforin-2 TRSSRAGLQFPVGRVHRLLRK Amp 











2.1.1. Cationic peptides 
Positively charged CPPs are widely seen and studied. Most of these peptides 
have several arginine or lysine residues in the primary sequences. Dedicated research 
about arginine residues in the peptides indicates that poly-arginine peptides (R7, R8, 
and R9) have better transmembrane capabilities than the original arginine-rich Tat 
(RKKRRQRRR) peptides [29, 30]. Meanwhile, other lysine-rich peptides including 
penetratin (RQIKIWFQNRRMKWKK) and TP-10 (AGYLLGKINLKAL-
AALAKKIL) have also shown great translocation efficacy. The high surface charge 
of cationic CPPs enables stronger membrane association, which increases the 
translocation efficacy. However, for some peptides, such as Tat and TP-10, these net 
charges and closer membrane association lead to membrane damage towards 
mammalian cells [31].  
2.1.2. Hydrophobic peptides 
Hydrophobic CPPs normally consist of several regions: a positively charged 
domain, a hydrophobic domain (h-region), as well as a negatively charged domain 
[32]. The hydrophobic domain controls the translocation of this class of peptides. The 
h-region of Kaposi fibroblast growth factor (AAVALLPAVLLALLAP, K-FGF) was 
incorporated into the SKP peptides, which showed intracellular translocation and 
nuclear localization [32]. The integrin β3 signaling peptide has an h-region with a 15-
amino acid fragment (VTVLALGALAGVGV) [5] that was used as a CPP for a 
translocation study in mammalian cells.  
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2.1.3. Amphipathic CPPs 
The amphipathic class of CPPs is the most commonly seen class. Upon 
forming their secondary structure, these peptides have a polar side with charged 
residues and a non-polar hydrophobic side with hydrophobic amino acids in the 
primary sequence. The helical structure, many of these amphipathic CPPs form, has 
been proposed to be directly related to their translocation process [33]. While 
amphipathic CPPs have a random coil conformation in aqueous solution, some 
studies indicate α-helical or β-sheet structures form when these peptides closely 
interact with the membrane [19, 34, 35]. The anionic cell membrane helps attract 
peptides onto the membrane surface through electrostatic forces, and the 
conformational transition due to the hydrophobic interaction from the non-polar 
residues promotes the insertion of the peptides into the lipid bilayer. Protein-derived 
CPPs like penetratin [6], pVEC [36], and CyLoP [37], as well as synthesized CPPs 
including MAP [38], KALA [19], and (KFF)3K [39], with such amphipathic 
properties have shown great translocation efficacy and structure transition behavior.  
2.1.4. Antimicrobial peptides 
Some peptides not only interact with the cell membrane, but also directly 
affect the viability of the cells. These peptides, commonly referred as AMP, include 
histatin-5 and cecropin A and B [40, 41]. Many members of this class of peptides 
have an amphipathic, α-helical conformation that promotes membrane interaction and 
leads to cytosolic toxicity to host cells [42]. Some AMPs, such as histatin-5 and 
S413-PV, target intracellular targets (mitochondria for histatin-5 [43]) and nucleus for 
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S413-PV [16]), whereas other AMPs, including tachyplesin I, cryptdin-4, and 
buforin-2, cause toxicity via pore formation [44].  
2.2. CPP translocation mechanisms 
 Although CPPs have been widely studied for decades, a clear explanation of 
the translocation process is still lacking. Initially, people believed that CPPs entered 
the cells via an energy-independent direct transmembrane process like pore formation 
[45]. However, more research has suggested multiple potential mechanisms (Figure 
2.1), including direct translocation (inverse micelles, "carpet", and pore formation) or 
endocytosis (for example, clathrin dependent endocytosis and macropinocytosis) [2].  
2.2.1. Direct translocation mechanisms 
Inverted Micelles. Penetratin, also known as pAntp, was the first peptide 
known to use the inverted micelles mode for internalization [6]. Based on results from 
 
Figure 2.1 Potential pathways of cell entry for CPPs. Figure from [21] 
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confocal microscopy, electron microscopy, [6] and NMR studies [46], Derossi et al. 
suggest that peptides initially associate with the lipid layers. Due to the hydrophobic 
interaction, peptides subsequently interact with the cell membrane and induce 
membrane reorganization and inversion. Hydrophobic residues like tryptophan, 
previously known as an inducer of inverted micelles [47], promote the formation of 
inverted micelles that carry the peptides. Although this mechanism explains how 
cationic CPPs that also have hydrophobic residues (like penetratin) can enter cells, it 
cannot explain the internalization of peptides that lack hydrophobic residues, such as 
the arginine-rich peptides (Arg)9 and SynB, since they cannot interact with the 
hydrophobic domain in the bilayer in the same way.  
Carpet Mode. The carpet mode of translocation was first proposed to 
describe the mechanism of the AMP dermaseptin S [25] and was later used to explain 
the mode of action for other peptides including AMPs and CPPs [22, 48-52]. The 
peptides first interact with the negatively charged membrane lipids such as 
phosphatidylinositol (PI), phosphatidylserine (PS), and phosphatidylglycerol (PG) via 
electrostatic interaction, triggering a conformational change of the peptides. The 
positively charged amino acid side chains turn towards the lipid hydrophilic surface, 
which allows the hydrophobic side chains to interact with the core of the bilayer. As 
the critical concentration of the peptides is reached, CPPs disrupt the membrane and 
cause internalization of the peptides [53]. The rearrangement of the peptides on the 
surface could also reduce the surface tension of the membrane, which would also 
promote the internalization of CPPs [53].     
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Pore formation. Pore formation has been observed mostly for amphipathic 
CPPs with a potential α-helical conformation upon membrane association. When 
many peptide units closely associate with the lipid membrane, they assemble into a 
"barrel", displaying all hydrophobic side chains outwards to allow deeper membrane 
association with the hydrophobic core. The bundled peptide clusters act like pores to 
permeabilize the membrane and allow more internalization of the peptides [53-55].  
2.2.2. Endocytosis-dependent mechanisms 
Instead of directly translocating into the cytosol of cells, CPPs internalized via 
endocytosis, commonly pinocytosis, are initially included in intracellular vesicles. 
These vesicles will be either guided to other cellular organelles [43, 56-58] or will 
escape from endosomes [59-62]. These pinocytosis processes can be classified into 1) 
clathrin-mediated, 2) caveolae-mediated, or 3) macropinocytosis.  Clathrin-mediated 
pinocytosis and caveolae-mediated pinocytosis are both receptor-mediated 
endocytosis processes that require specific membrane receptors to allow vesicles 
formation [63], whereas macropinocytosis is independent of a receptor [64]. Some 
peptides may adopt multiple mechanisms dependent on the concentration and the 
cargo properties. TAT was suggested to use caveolae-mediated endocytosis with 
protein cargo, but to utilize a clathrin-mediated process when attached to small 
molecules [53]. Macropinocytosis, a non-specific endocytosis process, was recently 
suggested to be a widely used mode of internalization [64, 65]. It can occur in 
different types of cells without a specific receptor requirement and is easily 
distinguished from other types of pinocytosis by the pattern of membrane 
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perturbation, where macropinocytosis involves actin cytoskeleton rearrangement at 
the plasma membrane leading to the formation of membrane ruffles [64]. 
2.2.3. Factors determining the translocation mechanism  
CPPs with different types of properties may have different modes of 
intracellular translocation and sometimes one CPP may even have multiple 
mechanisms. Several properties are useful in evaluating the mode of action for 
intracellular translocation, such as cargo type and size, concentration of the peptides, 
target cell type, amphipathicity of the peptide and net charge of the peptide. For direct 
translocation processes, physiochemical properties can greatly affect the efficacy of 
translocation [66, 67].  
In some cases, the biophysical (structural) properties of the peptides also 
affect the membrane association and translocation processes. The amphipathic 
property of CPPs and net surface charges of the peptides can greatly affect the 
interaction between peptides and cell membranes [68]. The primary sequence of the 
peptides and the hydrophobicity of the environment has a huge impact on the 
secondary structure of the peptides, which is closely related to the translocation 
mechanism [69]. CPPs like pVEC and penetration remain in random coil 
conformation in aqueous solutions but form helical structures in hydrophobic 
solutions or when interacting with model membranes [70]. Eiríksdóttir et al. 
suggested that conformational change can be directly associated with the membrane 
interaction and affect the translocation mechanisms and efficacy of peptides, such as 
MAP and TP10 [70].  
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2.3. Current applications of CPPs  
Since Tat was first discovered at 1988 [71], researchers have widely studied 
CPPs due to their great cargo delivery potential. Compared with other delivery 
methods, CPPs have some promising advantages, such as high delivery efficiency, 
specificity, and flexibility in cargo properties [57]. CPPs can translocate various types 
of biomolecules including DNA [10, 72-75], siRNA [76, 77], proteins [78-82], and 
nanoparticles [83]. These cargos can be either covalently conjugated to the peptides 
by chemical reaction or recombinant gene expression or non-covalently conjugated. 
The variety of properties and the high compatibility of different cargo molecules have 
allowed CPPs to become promising drug delivery vehicles.  
2.3.1. Protein cargo delivery 
Therapeutic proteins and peptides are great options for treating many diseases. 
People have been working with CPPs to deliver protein cargos with sizes ranging 
from 25 kDa (e.g. scFv [84]) to 150 kDa (e.g. IgG [85]). The 120-kDa protein β-
galactosidase can be delivered into mouse tissues, even in the brain, while 
maintaining its biological activity [86]. CPPs like Tat, penetratin, or Pep-1 have been 
shown to yield significant tissue localization in vivo with protein cargos consisting of 
antibody fragments ([87]). Not only useful in mammalian cells, CPPs can also deliver 
proteins into other types of cells including bacterial cells [88] and fungal pathogens 
[89, 90], suggesting CPPs can play a great role in drug delivery for different 
purposes.  
CPP-assisted protein delivery has shown therapeutic effects towards diseases 
such as cancer and strokes. Tat and penetratin successfully delivered elastin-like 
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polypeptides fused to a cyclin-dependent kinase inhibitor p21 that could inhibit 
proliferation of cancer cells [91]. Tat was also used to deliver a cellular antigen of 
CD8+ T cells, (Tp2), to stimulate CD8+ T cells. Other proteins delivered by CPPs 
include postsynaptic density protein PSD-95 [92] and Bcl-xL [93] and could also 
prevent tissue damage caused by cancer cells in vivo. Bigger molecules such as 
antibodies that are difficult to deliver intracellularly can also be translocated by CPPs. 
CPPs have successfully been used to deliver anti-mouse immunoglobulin (IgG) [94] 
and anti-p21 antibody for sensitizing cancer cells [95].  
2.3.2. Nucleic acid cargo delivery 
CPPs have been used to deliver nucleic acids for gene regulation related to 
diseases including cancer. Peptide-nucleic acid complexes, or polyplexes, allow easy 
conjugation and rational design to improve delivery efficacy and cellular targeting. 
Non-covalent conjugation of siRNA to MPG, a chimeric CPP with a nuclear-
localization sequence (NLS), allowed intracellular delivery into mammalian cells and 
in vivo gene regulation [96]. Palm-Apergi et al. showed that MAP, a model 
amphipathic CPP, can transport DNA or plasmid inside bacterial ghosts, empty cell 
envelopes of Gram-negative bacteria, into cancer cells without further lysis or ghost 
reloading [97].  When siRNA is encapsulated in liposomes, the poly-arginine CPP R8 
enhances the intracellular delivery of the nucleic acid and maintains the biological 
functions [98]. Tat was also studied to deliver the gene for GFP into HeLa cells with 
a high transfection efficiency and biological activity [99]. The easy conjugation and 
high translocation efficacy allows CPPs to be a promising tool for gene editing and 
gene therapy [100]. 
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2.3.3. Small molecule delivery 
CPPs have also been studied for delivering small molecules into cells via 
chemical conjugation of the CPPs to the small molecules. The arginine-rich CPP R9F2 
successfully delivered phosphorodiamidate morpholino oligomers with a high 
internalization efficacy and in vivo gene regulation function in cultures of primary 
murine leukocytes [101]. Cancer cells resistance to methotrexate (MTX) could be 
inhibited by conjugating MTX to YTA2 and YTA4 CPPs [102].  Longhu et al. used 
Tat to deliver 2′,5′-oligoadenylate tetramer (2-5A) to enable in vivo activation of 
RNase L, which provided a new method to destroy HIV RNA [103]. As more small 
molecule drugs are approved for treating cancer, CPPs could improve the therapeutic 
effects by increasing the specificity and efficacy. 
2.4. Limitations of CPPs in drug delivery 
Although CPPs are promising tools for drug delivery, they do have limitations 
that must be considered. For CPPs that enter the cells via endocytosis, endosomal 
escape is necessary for intracellular delivery. However, the exact mechanisms of 
endosomes escape are still unknown[59, 104]. After the release of the CPPs into the 
cytosol, the target loctation of the peptides is often non-specific and how the cellular 
targeting can be controlled is still not fully understood. Although the nuclear 
localization of CPPs like Pep-1 and MPG can be explained by the incorporation of an 
NLS sequence, a general explanation for other CPPs is still under debate.   
The cytotoxicity of CPPs could be a potential safety issue for applying CPPs 
to in vivo cargo delivery. The potential toxicity of cationic peptides from disrupting 
the cell membranes and affecting other cellular organelles would directly affect the 
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viability of host cells. Even though CPPs can be used to kill cancer or bacterial cells, 
the specificity of the peptides needs to be addressed to reduce nonspecific cargo 
delivery into normal cells.  
The stability of CPPs is another major issue that needs to be considered while 
studying CPPs for cargo delivery. As the surface charges are very important for the 
initial membrane association, the pH and ionic strength of the buffer hugely impacts 
translocation efficacy. Secreted proteases from the host cells can degrade the peptides 
before internalization happens, significantly reducing the efficacy of the peptides 
[105].  After internalization, the pH/salt concentration shift and intracellular proteases 
will also significantly affect the integrity of the peptides [106-108]. In addition, the 
immunogenicity of CPPs has not been fully studied [1, 109], so there is not clear 
understanding whether the immune system will rapidly eliminate peptides before 
internalization happens.  
2.5. Opportunities for studying CPPs in fungal pathogens 
Despite the limitations in applying CPPs in mammalian cells, the advantages 
of these short peptides can still be widely applied to fungal cells. Due to the limited 
work done previously in fungal cells, I explored the application of CPPs in treating 
fungal infections or delivering antifungal agents into pathogens to enhance the 
therapeutics. Studying translocation mechanisms from both biological and molecular 
perspectives will benefit the understanding of structure-function relationship of CPPs. 
My engineering work of rational CPPs design applies the knowledge of structure-
function relationships and enables better rational design of CPPs for improved 
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translocation efficacy, as well as specific cell targeting. This work has been done in 
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Chapter 3. Translocation of CPPs into Candida 
fungal pathogens1 
3.1. Introduction 
CPPs have shown great potential in drug delivery in mammalian cells and have 
been extensively studied to understand the translocation mechanisms. However, the 
structural and functional diversity of CPPs complicates studies of their interactions 
with cells. Previous mechanistic research on CPP translocation suggests some 
peptides penetrate cells via an energy-dependent endocytosis process. These CPPs 
include MAP (synthetic, highly amphiphilic model peptide [1]), TP-10 (fragment of 
transportan [2]), hCT (derivative of calcitonin [3]), SynB (derivative of the 
antimicrobial peptide protegrin 1 [4]), and PAF26 (hexapeptide with antimicrobial 
activity [5]). In contrast, other CPPs may enter cells via macropinocytosis [6], 
including pVEC (derivative of murine vascular endothelium cadherin [7]) and 
penetratin (fragment of antennaedia homeodomain [8]). The mechanism of 
translocation may also include transient pore formation [9], which is suspected for 
MPG (derivative of two viruses [10]) and Pep-1 (synthetic peptide [11]). MPG and 
Pep-1 also contain nuclear localization sequences, which promote the translocation 
efficacy and solubility of the peptides [9]. For other CPPs, such as (KFF)3K 
                                                 
1 This chapter has been accepted in the Protein Science Journal and appears in this thesis with the 
journal’s permission:  
Gong Z, Karlsson AJ 




(synthetic peptide [12]), additional work is required to elucidate the mechanism of 
translocation. These examples highlight the diversity of CPPs as delivery vehicles and 
the challenges in understanding their interaction with cells. 
Most studies on the translocation mechanisms of CPPs have focused on 
translocation in mammalian cells, and studies of the interactions of CPPs with fungal 
cells, including Candida cells, are very limited [13-18]. To expand the application of 
CPPs to delivering molecules to Candida species, an improved understanding of the 
interaction of CPPs with Candida cells is required. One key structural difference 
between mammalian cells and fungal cells is the presence of a cell wall in fungal 
cells. The cell wall is composed of chitin, glucans, mannans, and glycoproteins and 
provides an additional barrier for CPP transport into fungal cells compared to 
mammalian cells [19]. Another key difference is that fungal cells have vacuoles, 
which are involved in a number of biological processes in fungal cells, including 
endocytosis, pH and salt balance maintenance, and phosphate degradation [20]. The 
effect of these structures on CPP translocation and trafficking has not been described 
previously, and an understanding of their role will facilitate the use and design of 
CPPs for delivering molecular cargo to fungal cells.  
To improve the understanding of how CPPs translocate into fungal cells, we 
studied the translocation of known CPPs into two Candida pathogens, C. albicans 
and C. glabrata. We evaluated the translocation and toxicity of the CPPs and 
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explored their mechanisms of translocation. Some peptides previously shown to enter 
mammalian cells were also translocated into Candida species, while others exhibited 
little to no translocation. Our analysis of subcellular localization of CPPs provides 
insight into intracellular trafficking of the peptides, as well as translocation 
mechanisms. Further experiments to explore the translocation mechanism indicate the 
translocation of some CPPs in fungal cells may differ from the mechanisms proposed 
for mammalian cells. Our data suggest translocation of CPPs into fungal cells often 
correlates with toxicity toward the cells, but some peptides are taken up by Candida 
cells with little effect on viability.  






pVEC LLIILRRRIRKQAHAHSK 2209.7 +8 
(KFF)3K KFFKFFKFFK 1413.8 +4 
Penetratin RQIKIWFQNRRMKWKK 2246.8 +7 
MAP KLALKLALKALKAALKLA 1876.0 +5 
Pep-1 KETWWETWWTEWSQPKKKRKV 2848.3 +2 
hCT LGTYTQDFNKTFPQTAIGVGAP 2326.6 0 
SynB RGGRLSYSRRRFSTSTGR 2100.3 +6 
MPG GALFLGFLGAAGSTMGAWSQPKKKRKV 2807.4 +5 
PAF26 RKKWFW 950.2 +3 





a Includes only charges due to amino acid side chains (pH 7) and not N-




3.2. Materials and Methods 
3.2.1. Peptides 
The peptides listed in Table 3.1 were commercially synthesized at >95% 
purity with an N-terminal 5-carboxyfluorescein (FAM) (Genscript, Piscataway, NJ). 
The lyophilized peptides were reconstituted in sterile, ultrapure H2O and diluted to a 
final concentration of 10 mM Na2HPO4 buffer. 
3.2.2. Strains and culture conditions 
C. albicans strain SC5314 and C. glabrata strain ATCC2001 were purchased 
from American Type Culture Collection (ATCC, Manassas, VA). Candida cells were 
inoculated from yeast-peptone-dextrose (YPD) agar plates (1% w/v yeast extract), 2% 
w/v peptone, 2% w/v glucose, and 2% w/v agar) into 5 mL of liquid YPD medium 
(1% w/v yeast extract, 2% w/v peptone, and 2% w/v glucose) and grown overnight at 
30 °C while shaking at 230 rpm. The cells in the overnight culture were subcultured 
into 5 mL of fresh YPD medium at OD600=0.1 (equivalent to ~2 × 10
6 CFU/mL). The 
culture was then grown at 30 °C to OD600=0.5 (equivalent to ~1 × 10
7 CFU/mL) 
while shaking. Cells were harvested by centrifugation at 4,000 × g for 10 min and 
washed twice with 10 mM Na2HPO4 buffer before use in downstream assays. 
3.2.3. Fluorescence imaging  
For each peptide, 100 µL of peptide solution (2–100 µM), depending on the 
experiment) was prepared in 10 mM Na2HPO4 buffer, mixed with 100 µL of cell 
suspension containing 5×105 cells in 10 mM Na2HPO4 and incubated at 30 °C for 60 
min. Cells were collected by centrifugation at 5,000 ×g for 10 min at 4 °C and 
washed once with 10 mM Na2HPO4. The cell pellet was then incubated with 200 µL 
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of 0.025% trypsin (Invitrogen, Waltham, MA) at 37 °C for 10 min to remove surface-
bound peptide [21]. Cells were collected and washed again with 10 mM Na2HPO4. 
For vacuole staining, 1 µM of CellTracker Blue CMAC (Invitrogen Molecular 
Probes, Waltham, MA) was added into the washed cell suspension and incubated at 
ambient temperature for 10 min. To prepare the cells for imaging, cells were collected 
and resuspended in 5 µL of 10 mM Na2HPO4. The suspension was transferred to a 
glass slide and imaged using an Olympus IX83 fluorescence microscopy system 
(Olympus, Center Valley, PA). Propidium iodide (1 mg·ml-1; Invitrogen, Waltham, 
MA) was added immediately before imaging as needed to examine the membrane 
integrity. Differential interference contrast (DIC), GFP fluorescence, vacuolar stain 
fluorescence, and/or PI fluorescence images were taken using the automatic process 
manager of the CellSens Dimension software (Olympus), and images were analyzed 
using NIH ImageJ software [22]. 
3.2.4. Quantification of translocation 
To prepare the Candida cells for quantification by flow cytometry, procedures 
analogous to those for microscopy were followed. Fresh cells were treated with 
dilutions of each peptide (1 µM–50 µM) and treated with trypsin after incubation. 
After washing the cells with 10 mM Na2HPO4, the cells were resuspended in 150 µL 
of 10 mM Na2HPO4. Cell suspensions were analyzed for FAM and PI fluorescence 
using a BD FACSCanto II flow cytometer (BD Biosciences, San Jose, CA). Only 
single cells were selected for analysis, and the analysis was preformed using FlowJo 
software (FLOWJO Inc., Ashland, OR).  
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3.2.5. Antifungal activity assay 
In order to assess the antimicrobial activities of the peptides, a microdilution 
assay was performed. After subculturing cells and growing the culture to OD600=0.5, 
a 5×105 cells/mL cell suspension was prepared in 10 mM Na2HPO4. Serial dilutions 
(20 µL) of the peptides were prepared at 0.2 µM–50 µM in 96-well plates. A control 
containing 50 µM of free FAM in 10 mM Na2HPO4 buffer was used as a control. The 
cell suspension (20 µL) was then added into each well, and the plate was incubated at 
30 °C with vigorous shaking for 60 min. Treated cells were diluted 20-fold in 10 mM 
Na2HPO4 buffer, and 100 µL of diluted cell suspension was added into 100 µL fresh 
YPD medium in a new 96-well plate. Plates were incubated at 30 °C with vigorous 
shaking for 16 hours, and the OD600 of the wells was measured using a 96-well plate 
reader (BioTek, Winooski, VT). The percentage of killing was calculated from  
Killing (%) = (1-
OD600,peptide
OD600,control
)×100 (1)  
Minimal inhibitory concentrations were determined as the minimum concentration 
resulting in a 50% reduction in cell viability (MIC50). 
3.3. Results 
3.3.1. Translocation of CPPs in Candida species 
 To study the interaction of CPPs with Candida species, we selected peptides 
representing a variety of structures and native origins to study CPP translocation into 
Candida cells (Table 3.1 ). All peptides were synthesized commercially with an N-
terminal 5-carboxyfluorescein label (FAM), which served as the cargo for the CPP 
and as the reporter to detect translocation. Our set of peptides includes peptides 
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shown previously to translocate into mammalian cells (all CPPs) or microbial cells, 
including bacteria and fungi (pVEC, (KFF)3K, penetratin, MAP, PAF26, and TP-10) 
[13-18]. The CPPs pVEC, (KFF)3K, penetratin, and TP-10 were shown to enter C. 
albicans previously [14, 17]. Some peptides are thought to be transported by energy-
dependent endocytic mechanisms (MAP, hCT, TP-10, SynB, PAF26) or 
macropinocytosis (pVEC and penetratin), while others undergo pore formation 
(penetratin, MPG and Pep-1) or unknown mechanisms ((KFF)3K) [1-9]. We also 
included cecropin B, a well-known antimicrobial peptide with antifungal activity, to 
compare its translocation with peptides previously identified as CPPs. C. albicans and 
C. glabrata were selected as target cells, because they are frequently isolated from 
patients with candidiasis [26]. 
To screen the CPPs for translocation into Candida species, we incubated C. 
albicans and C. glabrata cells with each of the CPPs. We identified the CPPs that 
could cross the barriers of these fungal cells using fluorescence microscopy to 
visualize the location of the fluorescein-labeled peptides (Figure 3.1A and 3.1B). 
Cells were treated with trypsin prior to imaging to remove peptide associated with the 
cell surface [17, 21]. A high level of translocation efficacy was observed in both types 
of fungal cells for several peptides with a relatively high net charge (≥ +4), including 
penetratin, pVEC, MAP, SynB, (KFF)3K, and MPG. PAF26 and Pep-1, which have a 
lower net charge (< +4), showed limited levels of translocation, while hCT (no net 
charge) could not be detected entering the Candida cells. The antimicrobial peptide 
cecropin B (+ 9) exhibited a high level of translocation, suggesting cecropin B could 
function as a CPP in addition to an antimicrobial peptide.  
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We quantified translocation and the effect of peptide concentration on 
translocation in C. albicans and C. glabrata using flow cytometry. Single cells were 
identified, and the percentage of these cells positive for FAM fluorescence was 
determined for each species (Figure 3.1C and 3.1D). We detected a dose-dependent 
fluorescence signal for each of the peptides that showed substantial translocation in 
the fluorescence microcopy assay. The flow cytometry data confirmed the limited 
translocation for PAF26 and Pep-1 and the lack of translocation for hCT that we 
observed by fluorescence microscopy.  
 
 
Figure 3.1. Translocation of FAM-labeled CPPs into Candida cells. DIC and FAM 
fluorescence images for translocation into (A) C. albicans and (B) C. glabrata. Flow cytometry 
data for translocation into (C) C. albicans and (D) C. glabrata. Cells were incubated for 1 h at 
30 °C with 25 µM peptides for imaging or serial dilutions of peptides (1-50 µM) for flow 
cytometry. Surface-bound peptides were removed by trypsin prior to imaging or flow 
cytometry, and controls with free FAM were included. For (A) and (B), scale bar=10 µm. For 




For most of the peptides, the behavior in C. albicans and C. glabrata was very 
similar. The exception to this was TP-10, which showed significantly enhanced 
translocation in C. glabrata compared to C. albicans. Although these two species are 
closely related, they do have unique characteristics that could affect the interaction of 
the cells with CPPs. For example, they express different membrane-anchored 
proteases and other proteins [27, 28], which may alter degradation of CPPs and their 
interaction with the cell membrane.  
3.3.2. Subcellular localization of peptides 
To gain insight into the intracellular trafficking of the CPPs, we examined our 
microscopy images (Figure 3.1). In some images, peptides appeared to localize in the 
vacuole (e.g., see FAM image for PAF26 in Figure 3.1A). In other images, the 
vacuoles that typically are easily visible were no longer present (e.g., see DIC images 
for MAP and penetratin in Figure 3.1B). Yeast vacuoles are very important for 
maintaining homeostasis, and they are highly involved in transmembrane transport 
[20]. To better understand the relationship between CPP trafficking, vacuoles, and 
vacuole loss, we used CellTracker Blue, a yeast vacuole stain, to track the vacuoles 
during incubation of C. albicans cells with the peptide pVEC (Figure 3.2A). When 
cells were incubated with a low concentration of pVEC, they retained their vacuoles 
and exhibited colocalization of a low level of FAM fluorescence with vacuole stain 
fluorescence. At higher concentrations of peptide, we observed total loss of vacuole 
stain fluorescence, an enhancement of FAM fluorescence intensity, and a shift to c  
ytosolic fluorescence. For cells treated with 10 M of pVEC, the differential FAM 
fluorescence was most apparent. Cells retaining their vacuoles showed a brighter 
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vacuole stain signal but a weaker FAM fluorescence, whereas cells that lost vacuoles 
had a stronger cytosolic FAM signal and no vacuolar fluorescence. The differential 
fluorescence intensity arises from the sensitivity of the 5-FAM fluorescein derivative 
we used. 5-FAM is very sensitive to pH and exhibits higher fluorescence intensity at 
pH 7.5 and lower intensity at pH 6.6 [29]. Because the cytosolic pH (~7.4) is 
relatively higher than the one inside vacuoles (~6.2) [30], the fluorescence intensity 
of the peptides is lower in vacuoles than in the cytosol [31]. Vacuole loss can also be 
 
 
Figure 3.2. Intracellular distribution of pVEC in C. albicans at different peptide concentrations. 
(A) DIC and fluorescence microscopy images showing location of FAM-labeled pVEC and 
location of vacuoles in cells. (B) Flow cytometry data illustrating shift of FAM and vacuolar 
fluorescence. Cells were incubated with serial dilutions of pVEC (1-50 µM) at 30 °C for 1 h and 
treated with trypsin to remove surface-bound peptide. CellTracker Blue vacuolar stain was 
added, and the samples were incubated at room temperature for 10 min prior to analysis. For 
(A), scale bar=10 µm. 
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identified by using flow cytometry to observe the FAM signal shift as the peptides 
move from the vacuoles to the cytosol at higher concentrations (Figure 3.2B). We 
quantified the cellular localization by gating two distinct populations in the flow 
cytometry data: one with a stronger FAM intensity but no vacuole stain fluorescence 
and the other with both vacuole stain fluorescence and lower intensity FAM 
fluorescence. These data show that vacuole loss is associated with high levels of 
translocation of pVEC.  
Based on the results for pVEC, we used flow cytometry to evaluate the 
subcellular localization in C. albicans and C. glabrata for each of the peptides with 
significant translocation (Figure 3.3). Subcellular vacuole localization was observed 
for each of the CPPs, suggesting vacuoles are generally involved in the translocation 
mechanism of CPPs for fungal cells. However, the proportion of FAM-positive cells 
that exhibited vacuole localization was lower for some peptides (e.g., pVEC, 
penetratin) compared to other peptides (e.g., SynB, MPG, (KFF)3K) (Figure 3.4), 









Figure 3.3. Quantification of cellular location of CPPs in (A) C. albicans and (B) C. glabrata. 
Cells were incubated with serial dilutions of peptide (1-50 µM) at 30 °C for 1 h, washed with 
trypsin, and incubated with CellTracker Blue vacuolar stain at room temperature for 10 min. 
Flow cytometry data were collected for FAM (peptide) fluorescence and vacuolar stain 
fluorescence. The percentage of cells with FAM fluorescence and with both FAM and vacuolar 
fluorescence were quantified. Error bars represent the standard error of the mean for three 






Figure 3.4 Percentage of (A) C. albicans and (B) C. glabrata cells containing peptide that 
exhibit fluorescence intensity consistent with vacuolar localization. Following collection of 
the data in Figure 3, the ratio of vacuole- and FAM-positive cells to the total number of FAM 
positive cells was calculated. Error bars represent the standard error of the mean for three 
separate experiments (N=3). 
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3.3.3. Mechanisms for translocation of CPPs into fungal cells 
 Our localization experiments revealed the important relationship between 
vacuoles and translocation. Previous work with yeast vacuoles suggested vacuoles are 
involved in endocytosis [20, 32], so we next studied endocytosis of the CPPs. To 
explore whether the mechanisms of translocation in fungal cells involve endotytosis, 
we first studied the translocation process  in C. albicans under conditions that inhibit 
ATP synthesis. Most ATP-dependent processes, including endocytosis, are limited at 
4 °C [33]. Sodium azide (NaN3) also inhibits energy-dependent endocytosis by 
inhibiting the function of cytochrome-c-oxidase for ATP synthesis [34, 35]. We 
 
 
Figure 3.5 CPP translocation into C. albicans under conditions that inhibit energy-dependent 
endocytosis. Cells were incubated with peptides (10 µM) for 1 h. Control samples were 
incubated at 30 °C. Endocytosis was inhibited by adding 25 mM NaN3 or by changing the 
incubation temperature to 4 °C. The percentage of cells exhibiting FAM fluorescence was 
quantified by flow cytometry. Error bars represent the standard error of the mean for three 
separate experiments (N=3). Statistical significance was analyzed with a one-way ANOVA 
test (α= 0.05), and the number of asterisks indicates the level of significance (* for p ≤ 0.01 
and *** for p ≤ 0.0001). 
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observed a significant reduction in translocation for six of the eight peptides (cecropin 
B, MAP, SynB, MPG, (KFF)3K, and TP-10) in the presence of 25 mM NaN3 and at 
low temperature (Figure 3.5), suggesting these peptides utilize energy-dependent 
endocytosis as their translocation mechanisms. pVEC and penetratin were not highly 
affected by the addition of NaN3 or the lower temperature, suggesting an energy-
independent translocation process.  
Membrane destabilization is also involved in the translocation mechanism for 
some CPPs [4, 5, 25]. To evaluate whether membrane destabilization plays a role in 
translocation of the peptides in our study, we used propidium iodide (PI) to identify 
pore formation in the membranes during CPP translocation into C. albicans and C. 
glabrata. Cells are normally impermeable to PI, but PI fluorescence can be detected 
in cells with destabilized membranes, which typically represents cells losing viability 
[36]. Using fluorescence microscopy, we observed that pVEC, penetratin, MAP, and 
cecropin B contributed to membrane permeabilization of C. albicans at a moderate 
concentration (10 µM) (Figure 3.6A). We confirmed these results by flow cytometry 
(Figure 3.6B and 3.6C) and found almost all cells incubated with these peptides were 
both PI- and FAM-positive, indicating translocation of these peptides is correlated to 
cell permeabilization. In contrast, (KFF)3K, SynB, and MPG showed FAM 
fluorescence with little to no PI fluorescence, suggesting these CPPs did not lead to 
general defects in membrane integrity at this concentration. 
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3.3.4.  Toxicity of CPPs towards Candida cells 
Yeast vacuoles are necessary for cells to maintain homeostasis, so the loss of 
vacuoles due to CPPs may lead to toxicity toward fungal cells. To examine the 
Table 3.2. Antimicrobial activities of peptides 
 Minimum Inhibitory Concentration (MIC50, µM)a 
Cecropin B Penetratin pVEC MAP SynB (KFF)3K MPG TP-10 PAF26 Pep-1 hCT 
C. albicans 4 1 2 4 50 50 10 > 50 > 50 > 50 > 50 
C. glabrata 25 2 4 8 25 50 50 32 > 50 > 50 > 50 
 a MIC50 values are defined as the minimum concentration of peptide required to reduce growth of cells by 50%. 




Figure 3.6 Effect of CPPs on integrity of cell membrane. (A) DIC and fluorescence 
microscopy images showing CPP translocation and PI uptake in C. albicans. (B) Flow 
cytometry data indicating the percentage of cells with CPP translocation (FAM fluorescence) 
and with PI uptake in C. albicans. (C) Flow cytometry data indicating the percentage of cells 
with CPP translocation and with PI uptake in C. glabrata. Following incubation with FAM-
labeled CPPs (10 µM), cells were treated with trypsin and then incubated with PI for 1 min 
immediately prior to imaging or flow cytometry. For (A), scale bar=10 µm. For (B) and (C), 
error bars represent the standard error of the mean for three separate experiments (N=3). 
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toxicity of CPPs toward C. albicans and C. glabrata, we incubated the cells with 
serial dilutions of the peptides. At high concentrations of peptide, we observed 
significant toxicity toward both types of Candida cells for each peptide that exhibited 
substantial translocation (Figure 3.7), with minimum inhibitory concentrations 
(MIC50s) ranging from 1 µM to 50 µM (Table 3.2). Little to no antifungal activity 
could be detected for CPPs that exhibited very low levels of translocation (i.e., Pep-1, 
PAF26 and hCT in both species and TP-10 in C. albicans) (Figure 3.7), and MIC50s 
for these peptides were above 100 µM (Table 3.2). Incubation with free FAM did not 
lead to any viability loss of Candida cells compared to the cells incubated with only 
Na2HPO4 buffer (data not shown). Interestingly, the CPPs pVEC, penetratin, and 
MAP exhibited even stronger antifungal activity than the well-known antimicrobial 
peptide cecropin B. For many of the peptides the loss of viability could be due to the  
 
 
Figure 3.7 Toxicity of CPPs toward (A) C. albicans and (B) C. glabrata. Cells were 
incubated with serial dilutions of peptides (0.2-50 µM) for 1 h at 30 °C. Samples were 
diluted, mixed with YPD medium, and incubated at 30 °C for 16 h. Optical density (OD600) 
of the cultures was measured and converted to killing percentage. Error bars represent the 
standard error of the mean for three separate experiments (N=3). Dotted line represents 50% 
killing, which was used to determine the MIC50 (Table 3.2) 
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vacuole loss we observed in our microscopy and flow cytometry data, since vacuoles 
are essential for fungal cells in controlling the cellular osmotic pressure, salt balance, 
and pH [20, 37]. For the peptides that exhibited substantial PI permeability (pVEC, 
penetratin, and MAP), the loss of viability could also be due to membrane 
permeabilization, though it is not clear from our data whether the permeabilization is 
a cause or an effect of cell death. Between the two Candida species, C. glabrata 
tended to be less sensitive to toxicity of the peptides compared to C. albicans, which 
is consistent with previous research of antimicrobial peptides and other antifungal 
agents [38-40]. This difference in toxicity of CPPs and antimicrobial peptides 
between Candida species is not yet fully understood, though work has suggested that 
it may be due to the different compositions of the cell membranes and the presence of 
different membrane proteins [38, 40].  
3.4. Discussion 
Our evaluation of the interaction of CPPs with Candida cells provides insight 
into the biophysical properties that affect translocation, the mechanisms of 
translocation, and the toxicity of the peptides we studied. 
Our data indicate that net charge of the peptides plays a role in translocation, 
with higher levels of positive charge generally leading to higher levels of 
translocation. As the phosphate heads of the membrane lipid are negatively charged, 
positive charged residues in peptides will lead to electrostatic interactions that bring 
peptide in close contact with the cell membrane. CPPs with higher net charges (≥ +4) 
including pVEC, penetratin, MAP, SynB, (KFF)3K, MPG, TP-10 and Cecropin B 
would have stronger electrostatic interactions, which enables them to have a stronger 
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interaction with the cell membrane and explains their higher stronger translocation 
efficacy. In our experiments, we used a FAM label as the cargo for our peptides. This 
FAM label has a net negative charge of -3 at the pH of our experiments, which would 
reduce the overall net charge of the peptide-cargo constructs. Additional studies 
evaluating other cargo molecules will be important in understanding the impact of the 
peptide charge alone and in determining whether properties of cargo molecules 
strongly influence the translocation effects of the peptides. 
Although each of the CPPs was previously shown to translocate into mammalian cells 
[21, 41], only pVEC, (KFF)3K, penetratin, and TP-10 were previously shown to 
translocate into Candida cells [14, 17]. Our results indicate that many of the CPPs 
that function in mammalian cells do function in C. albicans and C. glabrata, but 
translocation into mammalian cells does not guarantee translocation in fungal cells. 
Three of the peptides tested showed little to no translocation in the two Candida 
species. In the case of Pep-1, association of the peptide with the cell wall contributed 
to the low level of translocation: when cells incubated with Pep-1 were imaged prior 
to trypsin treatment, the peptide was observed on the cell surface (Figure 3.8). 
However, for hCT and PAF26, the origin of the difference is less clear, since these 
peptides did not localize at the cell surface. 
Our results for subcellular localization, membrane stability, and endocytic 
inhibition together provide insight into the translocation mechanisms for the CPPs in 
fungal cells (Table 3.3). The combination of significant vacuolar localization,  lack of 
strong membane destabilization, and inhibition of translocation by NaN3 and low 
temperature suggests endocytosis is involved in the translocation of a peptide, and we 
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observed these characteristics for the translocation of SynB and (KFF)3K. Stronger 
cytosolic localization along with high PI permeability, as we observed at high 
concentrations for cecropin B, pVEC, penetratin, and MAP, indicates the possibility 
of direct translocation into the cytosol, though endocytosis might still be possible at 
concentrations resulting in vacuolar localization.  
Interestingly, the data for several of the peptides indicate multiple 
mechanisms may be involved in their translocation into fungal cells. For example, the 
NaN3 and low temperature data for pVEC suggest an energy-independent mechanism, 
such as macropinocytosis or direct pore formation, which is consistent with the PI 
data. However, the microscopy images and flow cytometry data (Figure 3.2) also 
indicate vacuolar trafficking, which is more consistent with energy-dependent  
 
Figure 3.8 Effect of trypsin treatment on localization of Pep-1. C. albicans cells were incubated with 
25 µM of FAM-labeled Pep-1 at 30 °C for 1 h. A portion of the cells were further treated with trypsin 
to remove surface-bound peptide, and the samples with and without trypsin treatment were imaged 




endocytosis. The possibility of multiple mechanisms is consistent with prior work 
with pVEC in mammalian cells. Elmquist et al. found that a clathrin-dependent 
endocytic pathway is involved in the translocation of pVEC, yet they still observed 
modest translocation at low temperatures to also implicate non-endocytic pathways 
[42]. Likewise, MAP and cecropin B have high PI permeability consistent with direct 
translocation, yet they exhibit the energy-dependent translocation and vacuolar 
trafficking consistent with endocytosis, which could indicate multiple mechanisms 
are also involved in translocation of these peptides.  
For some peptides, our results implicate a translocation mechanism in 
Candida cells that differs from previous studies with mammalian cells. MPG and TP-
10 were previously suggested to destabilize and make pores in the membrane of HeLa 
and melanoma cells, respectively [24, 25]. However, our PI data, NaN3 assay, and 
localization images indicate an endocytic process is involved for Candida cells. The 
Table 3.3. Summary of subcellular localization and potential translocation mechanism of CPPs 
 Cecropin B Penetratin pVEC MAP SynB (KFF)3K MPG TP-10 
Vacuolar 
localization 
Low Low Low Low High High High High 
PI 
permeabilitya 
++ ++ ++ ++ + - - - 
Endocytosis 
inhibition 
Yes No No Yes Yes Yes Yes Yes 
Potential 
mechanismb 
E/D M/D E/M E/D E E E E 
Reported 
mechanismb 
E/Dc E/Dd Me Df Ed n/a Dg Df 
a Strong PI permeability is indicated by ++, moderate permeability by +, and no significant  
   permeability by -.  
b Translocation mechanisms are as follows: endocytosis (E), macropinocytosis (M), direct 
translocation/pore formation (D), or no data available (n/a) 
c Reference [23] 
d Reference [4] 
e Reference [7] 
f Reference [24] 
g Reference [25] 
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difference in structure of the cell types may help explain this discrepancy. Hallbrink 
et al. and Simeoni et al. showed the translocation and pore formation of MPG, Pep-1, 
and TP-10 was associated with the close interaction between peptides and cell 
membranes [24, 25]. However, the additional barrier of the cell wall in fungal cells 
could interfere with this close interaction. This idea is consistent with our observation 
that Pep-1 associated with the surface and did not translocate into fungal cells 
(Figure 3.8). Additionally, differences in cell-surface properties and proteins could 
change the overall structure and behavior of CPPs. For example, Candida cells could 
have a receptor that recognizes MPG and TP-10, causing a shift in the translocation 
mechanism in fungal cells to endocytosis, even though membrane destabilization 
occurs in mammalian cells. 
Our vacuolar localization study and PI uptake investigation also highlighted 
the potential toxicity of CPPs towards fungal cells. CPPs like pVEC and penetratin, 
which showed significant intracellular (especially cytosolic) delivery, had a higher 
level of antifungal activity. The toxicity of these CPPs toward Candida pathogens 
could prove to be a positive feature of CPPs targeted to fungal pathogens, as one 
motivation for studying CPPs in fungal cells is to use them to deliver antifungal 
molecules, and the cytotoxicity of the CPP vehicles would potentially increase the 
therapeutic effects of the cargo being delivered. To function as a delivery vehicle for 
antifungal therapeutics, toxicity of the CPPs to host cells would need to be minimal. 
Previous studies suggest TP-10, penetratin, MAP, and cecropin B negatively affect 
mammalian cell viability [41, 43-46], which would complicate their use in delivery of 
antifungal therapeutics. In contrast, pVEC and MPG did not significantly reduce 
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viability of mammalian cells [41, 47], and we observed both strong translocation and 
strong toxicity toward fungal cells, suggesting these peptides would be promising 
candidates for delivering antifungal agents or could potentially serve as antifungal 
agents themselves.  
Although toxicity of CPPs may be desirable in the case of delivering 
antifungal molecules, CPPs also have potential in delivering non-toxic bioactive 
cargo to study the effect of the cargo on cellular function [48, 49]. In this case, 
toxicity from CPP vehicles would need to be as low as possible. While most of the 
peptides we studied would not be suitable for this type of application, SynB is the 
exception. At a concentration of 10 μM, essentially 100% of Candida cells were 
positive for peptide translocation (Figure 3.1C), while the same concentration led to 
a loss of viability for only 10% of C. albicans and 5% of C. glabrata cells (Figure 
3.7). SynB also has a low level of toxicity toward mammalian cells [50], further 
increasing its potential applications in studying the biology of Candida pathogens.  
Our data for the toxicity of the CPPs highlight the importance of considering 
the goal of cargo delivery in selecting a CPP. The level of CPP translocation, along 
with the toxicity toward the target cells and any other cells that may be present, must 
be evaluated to identify a CPP with the desired delivery and toxicity profiles. 
3.5. Conclusion 
We have identified a number of CPPs that are able to translocate into the 
fungal pathogens C. albicans and C. glabrata. Our work also explored the 
intracellular distribution of the CPPs following translocation into fungal cells and 
found that vacuoles play a significant role in CPP trafficking. Our results suggest that 
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translocation of CPPs into fungal cells may involve multiple mechanisms and that 
these mechanisms may lead to the toxicity observed for some peptides. Further work 
to explore the translocation mechanisms of CPPs could improve their efficacy and 
toxicity profiles to make CPPs viable therapeutic delivery agents. By increasing the 
translocation of bioactive cargo using CPPs, effectiveness of antifungal agents could 
be improved and new classes of molecules that currently lack the ability to cross cell 
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Chapter 4. Secondary structure of CPPs and the 
interaction with fungal cells 
4.1. Introduction 
In Chapter 3, we identified the CPPs that can be applied to fungal pathogens, 
for either cargo delivery or killing fungal cells and initiated studies of translocation 
mechanisms of CPPs to better understand the mode of action of the CPPs. In this 
chapter, we further explore the translocation mechanisms from the molecular level to 
develop an improved understanding of the reason for translocation and the difference 
in behavior for different CPPs.  
As we discussed in Chapter 3 and as suggested in previous CPPs research in 
fungal cells, the translocation mechanisms were studied with the help of fluorescently 
labeled peptides. This allows qualitative and quantitative study of uptake, subcellular 
localization and even membrane destabilization [1-4]. It also enables understanding 
of translocation mechanisms from biological perspectives, as energy dependence or 
membrane integrity can reveal whether the translocation is an endocytic process or 
direct translocation. However, fluorescent labelling of peptides cannot reveal exactly 
how these peptides interact with cells at the molecular level and what happens to the 
peptides upon interaction.  
Biophysical studies of CPPs have indicated that the structure of CPPs may be 
related to the overall translocation processes. Most of the biophysical studies were 
carried out using direct circular dichroism (CD) of peptides either in different 
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solvents or in a mixture of lipids or lipopolysaccharides to mimic cell membrane 
components [2, 5-8]. While CD data of CPPs in solutions provide information about 
the conformation of the peptides before the interaction happens, they fail in providing 
structural information while CPPs are very close to or on the cell surface. Model 
membrane or model lipid vesicles have been used to improve studies of peptide-lipid 
interactions by mimicking the phosphate lipid bilayers. According to previous studies, 
many CPPs like pVEC, TP-10, MAP, MPG, Pep-1, and Tat remain in a random 
conformation in aqueous solutions [6]. However, when lipid vesicles were added into 
the system, a higher order structure (β-sheet or α-helix) could be observed, and 
vesicle leakage was detected, which is analogous to membrane leakage for live cells 
[6]. Similar results were observed while different types of vesicles were added into 
the peptide solutions [9, 10]. Using lipid vesicles, researchers have proposed several 
modes of actions for the translocation of CPPs based on the CD spectra [11].  
However, cells are very dynamic and complicated systems, and these 
characteristics extend to the cell membrane and, in the case of fungal cells, the cell 
wall. Candida cell membrane lipids  include phosphatidylinositol (PI), 
phosphatidylserine (PS), phosphatidylglycerol (PG), phosphatidylcholine, 
phosphatidylethanolamine, and  phosphatidylinositol [12], and the lipid composition 
can vary between azole sensitive and insensitive stains. In addition, a number of 
anchored proteases such as secreted aspartic proteases (Saps) could potentially affect 
the interaction of CPPs with membrane as they might degrade the peptides [13, 14].  
Model membranes or vesicles enable the understanding of the interaction between 
lipid bilayers and the peptides due to the electrostatic force or hydrophobic 
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interaction, yet fail to take these cell-surface embedded proteins into account. In 
addition, the higher tendency of aggregation of lipid vesicles complicates the 
structure of the vesicles while interacting with peptides. Hence, model vesicles have 
some disadvantages in predicting the interaction of CPPs with lipid bilayers.  
To address the limitations of using model cell membranes, Concetta et al. 
recently reported using CD spectroscopy to directly study the interaction between 
antimicrobial peptides, which are similar in structure and function to CPPs, with 
bacterial cells [15, 16]. Details of the initial interaction of peptides with cells can be 
resolved by CD measurement in the presence of the whole cells, and the time-lapse 
measurement provides the long-term conformational change due to the interaction.  
Using this approach yields molecular-level understanding of the peptide-membrane 
interaction that can be directly compared to data on CPP translocation. 
In this study, we applied the direct CD measurement with whole cells 
developed by Concetta et al. to the fungal pathogen C. albicans to not only 
understand the structure of CPPs in the presence of the cell membrane, but also to 
determine what causes the conformational transition when CPPs are near the cell 
surface. In addition, we used Monte Carlo simulation to understand the initial 
interaction of CPPs with a model lipid layer to gain a residue-level understanding of 
the mode of action and the conformational transition upon interaction with a lipid 
membrane for peptides with helical secondary structures. The present study allows us 
to look closely at the cell surface and discern a biophysical explanation of secondary 
structure formation and translocation mechanisms of CPPs during their interaction 
with C. albicans 
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4.2. Materials and methods 
4.2.1. Peptides 
The peptides used in this study (Table 4.1) were commercially synthesized 
with an N-terminal 5-carboxyfluorescein (FAM) and a purity > 90% (Genscript). The 
lyophilized peptides were reconstituted in either 10mM Na2HPO4 buffer, 2, 2, 2-
trifluoroethanol (TFE), or a mixture with a buffer/TFE ratio of 1:1 (v/v), depending 
on the assay.  
4.2.2. Strains and culture conditions 
The fungal pathogen C. albicans SC5314 was purchased from the American 
Type Culture Collection (ATCC). Cells were first inoculated from a yeast-peptone-
dextrose (YPD) agar plate into 5 mL of YPD liquid medium and grown overnight 
while shaking at 230 rpm. The overnight cell culture was subsequently subcultured 
into 5 mL of fresh liquid YPD at OD600=0.1. The culture was grown at 30 °C with 






pVEC LLIILRRRIRKQAHAHSK 2209.7 +8 
Penetratin RQIKIWFQNRRMKWKK 2246.8 +7 
MAP KLALKLALKALKAALKLA 1876.0 +5 
Pep-1 KETWWETWWTEWSQPKKKRKV 2848.3 +2 
SynB RGGRLSYSRRRFSTSTGR 2100.3 +6 
MPG GALFLGFLGAAGSTMGAWSQPKKKRKV 2807.4 +5 





a Includes only charges due to amino acid side chains (pH 7) and not N-




shaking to mid-log phase (~4h with an OD600=0.5). Cells were collected by 
centrifugation at 4,000 × g for 10 min and washed with 10 mM Na2HPO4 buffer twice 
before finally resuspending in 10 mM Na2HPO4 buffer with a final OD600=0.2 (~ 
4×106 CFU/ml) before the assays.  
For experiments involving a cell lysate, the lysate was prepared from mid-log 
phase cells. Subcultured cells were lysed in 10 mM Na2HPO4 buffer using a 
homogenizer (Avestin) and diluted to the equivalent of 4×106 CFU/ml. 
4.2.3. Circular dichroism 
CD spectra were collected at 30 °C using a micro-cuvette quartz cell with a 10 
mm path length (Fisher Scientific). The CD spectrometer J-810 (Jasco) was set to 
scanning mode with a 190-240 nm range, 50 nm/min scanning speed, 1 nm 
bandwidth, 1.0 nm data pitch, and 3-accumulation mode. For CPPs in solutions, the 
measurement was performed with 400 µL of 5 µM peptide solution in Na2HPO4 
buffer, TFE, and a mixture with a buffer/TFE ratio of 1:1 (v/v). The signal was 




     (Equation 4.1) 
where θ is the ellipticity (degrees), C is the molar concentration (M), and l is the cell 
pathlength (cm). 
For CD with live fungal cells, 200 µL of a prepared cell suspension or cell 
lysate was mixed with 200 µL of 10 µM peptide solution in Na2HPO4 buffer to 
achieve a final peptide concentration of 5 µM and a final cell concentration of 2 × 106 
CFU/ml. Due to the existence of cells, the ellipticity cannot be converted from 
[mdeg] to molar ellipticity. The mixture was either immediately measured by CD or 
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incubated for 30 min at 30 °C before CD measurement. All experiments were 
performed with three replicates. 
4.2.4. Membrane depolarization assay 
Membrane depolarization was evaluated using 3,3'-dipropylthiadi-
carbocyanine iodide (DiSC3(5)). Subcultured C. albicans cells were washed twice 
with 10 mM Na2HPO4 buffer and concentrated to a final OD600=1.0. DiSC3(5) 
(ThermoFisher) was diluted to a stock concentration of 1 M in DMSO. A volume of  
990µL of cell suspension was added to a glass micro-cuvette, and the fluorescence 
emission was measured using a fluorometer (Molecular Devices; 633 nm excitation 
and 666 emission filters). This concentrated cell suspension containing no peptide 
was used to measure the baseline fluorescence level for 60 sec with data collected 
every 3 sec. The DiSC3(5) stock solution (1 µL) was added into the suspension and 
the fluorescence was measured for another 120 sec with 3 sec data pitch until the 
reading reached a steady level. A volume of 10 µL of 50 g/L glucose stock solution 
was added into solution to further reduce the fluorescence level for another 120 sec 
with 3 sec data pitch. A volume of 10 uL of peptides solution (1 M) was added into 
the solution, and the fluorescence signal was measured for 600 sec. All experiments 
were performed with three replicates. 
4.2.5. Monte Carlo simulation for helical peptides 
Monte Carlo simulations of the peptides that can form helical structures were 
performed using the MCPep server (available online at http://bental.tau.ac.il/MCPep/) 
[17]. The hydrophobicity of the membrane was represented as a smooth profile of 30 
Å width, similar to a fungal cell membrane [8], with the hydrophobic surface at a 
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distance of 20 Å from the mid-plane. The negative charge was estimated based on the 
composition of C. albicans cell membranes [12], i.e., 20 % phosphatidylinositol + 17 
% phosphatidylserine (PS) + 3 % phosphatidylglycerol (PG) = 40% charged lipids. 
The solution was set to contain 0.01 M monovalent salts. Three independent runs of 
the simulations were performed with 500,000 MC cycles in each run. The total free 
energy of membrane association was calculated as the difference between the free 
energies of the peptide in water and in the membrane. The average distance to the 
mid-plane and the helical content percentage of each individual residue were also 
determined in the simulation.  
4.3. Results 
In Chapter 3, I identified the CPPs that can translocate into Candida cells, 
such as pVEC, SynB, and the antimicrobial peptide cecropin B. In addition, I 
explored the translocation mode of action of these peptides from a biological 
perspective by evaluating pore formation and endocytosis. To better understand the 
translocation and mode of action from the molecular level, this study focused on the 
biophysical properties of CPPs, in particular the secondary structure, and how these 
properties affect the membrane association of the peptides, as well as the 
internalization mechanisms. 
4.3.1. CPP structure in solution 
Several CPPs have the ability to translocate into the fungal pathogen 
C. albicans. We evaluated the structure of 8 of those peptides (Table 4.1) in solution 
to gauge the solvent effect on secondary structure formation. The CD spectra of these 
peptides in aqueous solution suggest that all of the peptides, except Pep-1, remain as 
 
65 
random coils in a hydrophilic environment. Pep-1 exhibits a weak minimum at 
208/222 nm, which is characteristic of helical structure (Figure 4.1). The secondary 
structures of all these peptides were previously studied in the solutions [5-8], and our 
results are consistent with those data. 
Although the peptides have little to no secondary structure in aqueous 
solution, the hydrophilic solution does not truly represent the environment of the 
peptides when they insert into the hydrophobic domain of the membrane’s lipid 
bilayer. Thus, we also examined the structure of these peptides in TFE to mimic this 
hydrophobic environment and better understand how the peptides behave in 
membranes (Figure 4.1). Consistent with previous research [6], all peptides except 
SynB showed a conformational transition from random coil (or weak helix, in the 
case of Pep-1) to α-helix. Unlike the other peptides, SynB showed a β-sheet structure 
in 50% TFE and switched to a more helical dominant conformation in pure TFE, 
suggesting that the secondary structure of SynB depending on the degree of 
hydrophobicity of its environment. Overall, these results suggest that the formation of 
secondary structure for these peptides requires a hydrophobic environment, such as 
that of the cell membrane, and that the peptides are unlikely to maintain a helical 
structure in an aqueous buffer.  
4.3.2. Circular dichroism with fungal cells 
Previous studies of CPP-membrane interactions were conducted with model 
lipid vesicles and structure information was measured by CD, but these measurements 
fail to take the complexity of the cell matrix into account. To account for this 
complexity, we evaluated the interaction between peptides and C. albicans cells by  
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using CD (Figure 4.2). A suspension of C. albicans with no peptide was used to 
measure the baseline CD spectrum, and this baseline was subtracted from the spectra 
of peptides in cell suspensions, as suggested by Concetta et al. [15, 16]. As the molar 
concentration of cells cannot be converted to a meaningful molar ellipticity, we report 
our results in [mdeg]. The far-UV spectrum of each peptide was scanned after the 
addition of C. albicans cells. We did not observe any effects due to the intracellular 
contents, as there was no observable difference in the spectra for peptides in solution 
and peptides treated with soluble cell lysates (Figure 4.2). Due to significant noise in 
the far-UV range, the concentration of peptides cannot be higher than 5 µM. The CD 
spectra of 5 µM peptides with C. albicans cells indicated no conformational change 
was evident for penetratin, MPG or Pep-1. MPG and penetratin remained as a random 
coil, and Pep-1 showed an α-helical structure at all tested conditions. In contrast, the 
remaining peptides exhibited a structural transition. For MAP and cecropin B, the 
transition was rapid. The random coil structure shifted to an α-helical structure within 
30 min of the addition of the cell suspension into the peptide solutions (Figure 4.2). 
These peptides have a strong amphipathic helical structure with all positively charged 
residues located on one side of the helix (Figure 4.3), which could promote 
interaction of the peptides with the negatively charged lipid head groups in the cell 
membrane. For  pVEC and TP-10, the conformational transition to helical structure 
became apparent after 30 min of incubation with cells, suggesting these peptides 
respond to the interaction with the membrane in a slower manner, which might be due 
to the imperfectly aligned charge on the surface compared with a model amphipathic 
























































































































































































































































































instead of a helix, indicating a conformational transition to a different secondary 
structure than seen for the other peptides, consistent with the 50% TFE solution in the 
results for peptides in solution. 
4.3.3. Simulations of peptide-membrane interactions 
 Our CD data suggest conformational change when CPPs are near the cell 
membrane. To help understand this behavior for the peptides that showed helical 
structures while interacting with cells, we used Monte Carlo (MC) simulations to 
model the interaction of the helical peptides with the C. albicans cell membrane. 
SynB was not included in the simulation as it formed β-sheet conformation upon 
interaction with fungal cells, and our simulation approach is not appropriate for 
peptides that form β-sheets [17]. The membrane was set up based on previous 
research about C. albicans membranes and membrane compositions. The thickness of 
the membrane was set to 30 Å [8] and the percentage of charged lipid was set to 40% 
(20 % PI + 17 % PS + 3 % PG based on the average reported lipid composition of C. 
albicans [8, 9]). The solution was assumed to be a buffer with 10 mM of monovalent 
salts, similar to our cell-based experiments.   
One parameter we evaluated was the free energy of membrane association 
(Table 4.2) [17]. For all the peptides, the membrane association free energy was 
negative, and the electrostatic term (ΔGcoul) dominated the free energy, indicating all 
the peptides spontaneously interact with the membrane due to the electrostatic force 
between the positively charged peptides and the negatively charged lipid head groups. 
Interestingly, the free energies of hydrophobic interaction (ΔGSIL) and conformational 
change (ΔGconf) for pVEC, MAP, TP-10, and cecropin B were significantly negative 
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compared with penetratin, Pep-1, and MPG. This suggests that, not only can they 
interact with the hydrophilic domain of the membrane, but also with the hydrophobic 
domain, resulting in the conformational change. These peptides exhibited a 
conformational shift in our CD measurement (Figure 4.2), which can be explained by 
this negative ΔGconf. As discussed earlier, hydrophobic interactions are the driving 
force of the secondary structure formation for all the peptides (Figure 4.1). Thus, the 
negative ΔGSIL is consistent with the shift in CD spectra and the negative ΔGconf for 
these peptides. For the peptides that did not show the evolution of secondary structure 
while interacting with Candida cells (penetratin, Pep-1, and MPG), the only force that 
substantially contributed to the membrane association was the ΔGcoul, indicating these 
peptides interact with the surface of the cell membrane and not with the hydrophobic 
lipid tails deeper within the core of the bilayers.  
We also simulated the conformation of the peptides on the surface to seek a 
biophysical explanation of our observations during the CD measurements (Figure 
4.4).  For the peptides that showed a negative ΔGconf and ΔGSIL (Table 4.2), the 
simulations showed that the peptides either partially inserted (pVEC and TP-10) or 
fully inserted (MAP and Cecropin B) into the hydrophobic core of the membrane, 
compared to the peptides that remained on the surface of membrane and did not show  
 
Table 4.2 Membrane association free energy calculation from Monte Carlo simulation 
Peptides ΔGTotala (kT) ΔGconfb (kT) ΔGSILc (kT) ΔGcould (kT) ΔGdefe (kT) 
pVEC -28.58 -2.09 -9.95 -16.79 0.25 
Penetratin -16.46 0.16 1.07 -17.95 0.25 
MAP -27.25 -1.20 -10.3 -16.53 0.25 
Pep-1 -11.28 -0.60 0.90 -11.69 0.25 
MPG -17.57 -1.68 -2.74 -13.40 0.24 
TP-10 -22.88 -1.37 -9.54 -12.22 0.26 



























































































































































































































































































































































































































































































































































































































































a conformational transition in the CD spectra (penetratin, Pep-1, and MPG). 
Furthermore, the inserted residues showed an increase in helical content, suggesting a 
stronger preference for formation of α-helical secondary structure. Surprisingly, MPG 
and Pep-1, which did not show a structural transition in the CD experiment with cells 
but did show an energetically favorable structural transition in free energy 
calculations, exhibited increased helical content. This could be explained by the 
difference in cells and the simulated membrane. The simulation relies on direct 
interaction with the membrane, which could be affected by the existence of the cell 
wall in live-cell experiments with these peptides.  
Overall, our MC calculations and simulations successfully explain the 
experimental data and help us build the connection between the membrane 
association and structure of CPPs. 
4.3.4. Membrane depolarization assay 
As we observed from our simulation results, interaction with the membrane 
core is possible for some CPPs. These close interactions with the core may potentially 
affect the integrity of the membrane [1]. To understand the biophysical interaction of 
these peptides with the membrane and the biological effect on the cells, we used a 
membrane depolarization assay with DiSC3(5), a dye that is sensitive to membrane 
potential. A total of 1 × 107 C. albicans cells was suspended in 1 mL of 10 mM 
Na2HPO4 buffer. The cell suspension was used to measure the baseline fluorescence, 
and the release of DiSC3(5) was measured for 600 sec (Figure 4.5). pVEC, 
penetratin, and cecropin B, which showed the potential for  direct translation in our 
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previous work with C. albicans [1], exhibited significant membrane depolarization  
within the first 100 sec after adding peptide to the cells. MAP exhibited a different 
behavior, where it depolarized the membrane rapidly, indicating strong membrane 
binding and interaction, likely due to its high amphiphilicity and high net charge. 
However, a hyperpolarization was observed after 700 sec. This has been observed for 
peptides in other studies [21-23], though the explanation is not clear. One possible 
cause could be internalization of the peptides, as internalization would reduce the 
amount of surface-bound peptide that is able to depolarize the membrane. SynB, 
MPG, Pep-1 and TP-10 showed results very similar to the control, suggesting 
                             
Figure 4.5. Evaluation of membrane depolarization. The fluorimeter was set with a 633 nm excitation and 
666 nm emission. A total of 1 × 107 C. albicans cells suspended in 1 mL of 10 mM Na2HPO4 buffer was 
added in the cuvette and used to measure the base line of fluorescence level. The base line was measured 
for 60 sec before DiSC3(5) (3,3'-Dipropylthiadicarbocyanine Iodide, 1 mM) was added into the cuvette. 
The maximum uptake of DiSC3(5) was observed at 180 sec. 10 µL of 20% glucose was added to further 
decrease the fluorescence level until 300 sec. Peptides were added into the cuvette to a final concentration 
of 10 µM and the release of fluorescence was monitored for 600 sec with a 3 sec measurement integral. 





minimal membrane depolarization is involved during their interaction with 
membrane.  
4.4. Discussion 
As indicated in previous research, many well-known CPPs remain in a 
random conformation in aqueous solutions [5, 18-20]. Our results support this 
observation and also suggest that peptides in the vicinity of the cell membrane, but 
not inserted into the membrane, remain in a random coil conformation (Figure 4.1). 
The observation of secondary structure under the hydrophobic solution suggests these 
peptides are capable of forming secondary structures, but that the conformation shift 
does not happen unless the peptides are in a hydrophobic environment, such as the 
core of the bilayers.  
Previous attempts to understand the interactions of CPPs with membranes 
were focused on gaining structural information through interactions with model 
membrane or vesicles or in hydrophobic solvents. However, neither approach reflects 
the real situation on the surface of cells. The cell surface with proteins, glycans, and 
the cell wall is complex and is likely to affect the interaction between the peptides 
and the membrane. Experimental methods that can take these into account need to be 
developed to give a more accurate representation of the membrane association. Our 
CD measurements along with our MC simulations provide a comprehensive 
understanding of secondary structure formation during the interaction of peptides 
with cells. The primary sequence of the peptides and the amphipathicity subsequently 
affect the extent of interaction. Those peptides showing a CD signal shift and 
negative confirmation free energy (Figure 4.2, 4.4, Table 4.2) were previously 
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shown to use a more aggressive direct translocation mechanism, which relies on the 
interaction of the peptides with the hydrophobic core of bilayers [1], which is 
consistent with our current observation. Membrane penetration allows access to the 
hydrophobic tail of membrane lipids, driving the formation of secondary structure, as 
we observed in this study (Figure 4.1, Table 4.2). 
In addition, our membrane depolarization data, along with CD and simulation 
data, enable a more detailed understanding of the translocation mechanisms. We 
previously found that Pep-1, SynB, and MPG use an endocytic pathway to gain 
intracellular access without affecting membrane integrity or the viability of cells [1]. 
This would require only brief interaction with the membrane. In this study, these 
peptides showed no secondary structure formation during interactions with cells and 
no significant membrane depolarization, suggesting the interaction between the 
peptides and cells stays on the top layer of the membrane, which is consistent with 
endocytosis. On the other hand, aggressively penetrating peptides like  pVEC, MAP, 
and cecropin B deeply inserted into the membrane, showed structural transition and 
membrane depolarization, consistent with our previous work [1] that shows damage 
to membrane integrity to allow the translocation.  
Our CD and MC simulation methods provide a great platform for 
understanding the structure-function relationships of helical CPPs. Given that MC 
simulation can predict how the peptides interact with membranes and how the 
interaction is related to the translocation mechanism, cell-specific, rational peptides 





Our results show for the first time that we can use CD to detect secondary 
structure transitions for CPPs during their interaction with the fungal pathogen 
C. albicans. Although CPPs may remain unstructured in aqueous solution, CD spectra 
and MC simulations, combine to indicate that, while electrostatic forces dominate the 
surface interaction between the helical peptides and the membrane, a closer 
interaction with the hydrophobic domain of the bilayers promotes a structural 
transition and leads to insertion and membrane disruption. These data from each of 
our approaches strongly correlate with each other, as well as previous CPP research in 
fungal cells. Our methods provide a platform for understanding the structure-function 
relationships of CPPs and for predicting the behavior of CPPs at the molecular level, 
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In Chapter 3, I identified the CPPs that can be applied to target fungal 
pathogens. I validated the idea of utilizing CPPs for cargo delivery and treating fungal 
infections caused by C. albicans, even though the peptides were initially discovered 
or designed for mammalian cell studies. However, not all the peptides we screened 
can translocate into fungal cells, suggesting that CPPs can be specific for different 
species, suggesting additional study of the properties of CPPs that affect the 
translocation mechanisms and specificities.  
In Chapter 4, we explored the mechanisms of membrane association and 
related that to our translocation studies to seek a molecular explanation for cell entry 
of CPPs. The charge and the hydrophobicity play important roles in determining the 
translocation mechanisms. As previous work suggested, peptide-cell interactions and 
toxicity are directly related to charge and hydrophobicity [1, 2]. Rationally designed 
peptides with a higher net charge affected the cell viability more significantly [1, 2]. 
Karagiannis et al. also suggested that the net charge of short peptides does not only 
affect the membrane association, but also could facilitate deeper membrane 
interaction of the hydrophobic residues [3]. Thus, net charge and hydrophobicity of 




Understanding the structure-function relationship will also benefit the rational 
design of CPPs for specific cell types, such as only targeting fungal cells without 
attacking host mammalian cells. Previous work with antimicrobial peptides showed 
that the properties of peptides affect the selectivity of the peptides for C. albicans and 
human red blood cells [2], indicating the potential in modulating peptide properties to 
modulate specificity. pVEC was previously shown to only affect the viability of 
microbial cells [4-8], without reducing the viability of mammalian cell lines [5, 9], 
making it a promising candidate for further engineering to enhance targeting of fungal 
cells. SynB was also studied as a “safe” cargo delivery vehicle for both mammalian 
cells and C. albicans. This provides another opportunity to engineer CPPs for 
specificity [8, 10] and allow cargo delivery without toxicity. 
In this study, we designed new CPPs based on the two well-studied peptides, 
pVEC and SynB, to understand the structure-function relationship and to improve the 
specificity and efficacy of CPPs towards a fungal pathogen. Our data indicate that net 
charge of peptides positively correlates with the translocation efficacy and the 
antifungal activity of the peptides. CPPs with high net charges tend to enter cells via 
direct translocation and traffic to the cytosol, which is promoted by a close interaction 
with the membrane. The hydrophobicity does not directly affect the translocation 
efficacy; however, it alters the membrane association pattern and affects the 
translocation mechanisms. Our newly designed peptides do not significantly affect 
the viability of mammalian cell lines, suggesting a promising opportunity to apply 
them for directly killing fungal pathogens around normal host tissues. Overall, our 
rational design of CPPs helps build understanding of CPPs to predict their behaviors 
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against both fungal cells and mammalian cells and to design them for desired 
interactions.  
5.2. Materials and methods 
5.2.1. Peptides 
The peptides listed in Table 5.1 were commercially synthesized at >95% 
purity with an N-terminal 5-carboxyfluorescein (FAM) (Genscript, Piscataway, NJ). 
The lyophilized peptides were reconstituted in sterile, ultrapure H2O and diluted to a 
final concentration of 10 mM Na2HPO4 buffer.  
5.2.2. Candida strains and culture conditions 
C. albicans strain SC5314 was purchased from American Type Culture 
Collection (ATCC, Manassas, VA). Candida cells were inoculated from yeast-







 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18    
pVEC L  L I I L R R R I R K Q A H A H S K +8 44% Original 
1 L L I I L R R R I R K R A H A H R K +10 44% Increase charge 
2 L L I I L R R S I R K Q A H A S S K +6 44% Decrease charge 
3 L L I I L S R R I R K Q A S A H S K +6 44% Decrease charge 
4 L L I I L R R R I R K L A H A H L K +8 56% Increase Hydrophobicity 
5 L L I I L R R R I R K Q S H S H S K +8 33% Decrease Hydrophobicity 
6 L S I I S R R R I R K Q A H A H S K +8 33% Decrease Hydrophobicity 
SynB R G G R L S Y S R R R F S T S T G R +6 16% Original 
1 R G G R L K Y R R R R F S T S T G R +8 16% Increase charge 
2 R G G R L S Y S R R R F K T R T G R +8 16% Increase charge 
3 R G G S L S Y S R R R F S T S T G S +4 16% Decrease charge 
4 R G G R L S Y S S R S F S T S T G R +4 16% Decrease charge 
5 R G W R L A Y A R R R F S T S T G R +6 39% Increase Hydrophobicity 
6 R G L R L L Y S R R R F S T L T G R +6 39% Increase Hydrophobicity 
7 R G G R S S S S R R R F S T S T G R +6 6% Decrease Hydrophobicity 
8 R G G R S S S S R R R F K T R T G R +8 6% 
Decrease Hydrophobicity 
Increase charge 




peptone-dextrose (YPD) agar plates (1% w/v yeast extract), 2% w/v peptone, 2% w/v 
glucose, and 2% w/v agar) into 5 mL of liquid YPD medium (1% w/v yeast extract, 
2% w/v peptone, and 2% w/v glucose) and grown overnight at 30 °C while shaking at 
230 rpm. The cells in the overnight culture were subcultured into 5 mL of fresh YPD 
medium at OD600=0.1 (equivalent to ~2 × 10
6 CFU/mL). The culture was then grown 
at 30 °C to OD600=0.5 (equivalent to ~1 × 10
7 CFU/mL) while shaking. Cells were 
harvested by centrifugation at 4,000 × g for 10 min and washed twice with 10 mM 
Na2HPO4 buffer before use in downstream assays. 
5.2.3. Quantification of translocation 
For each peptide, 100 µL of peptide solution (2–100 µM), depending on the 
experiment) was prepared in 10 mM Na2HPO4 buffer, mixed with 100 µL of fungal 
cell suspension containing 5×105 cells in 10 mM Na2HPO4 and incubated at 30 °C for 
30 or 60 min. Cells were collected by centrifugation at 5,000 ×g for 10 min at 4 °C 
and washed once with 10 mM Na2HPO4. The cell pellet was then incubated with 200 
µL of 0.025% trypsin (Invitrogen, Waltham, MA) at 37 °C for 5 min to remove 
surface-bound peptide [11]. Cells were collected and washed again with 10 mM 
Na2HPO4. For yeast vacuole staining, CellTracker Blue CMAC (Invitrogen 
Molecular Probes, Waltham, MA) was added into the washed cell suspension at 1 µM 
and incubated at ambient temperature for 10 min. Propidium iodide (PI, 1 mg·ml-1; 
Invitrogen, Waltham, MA) was added at 0.2 mg·ml-1 immediately before imaging as 
needed to examine the membrane integrity. For quantification of translocation, the 
cells were resuspended in 150 µL of 10 mM Na2HPO4 after trypsin treatment and the 
final wash. Cell suspensions were analyzed for FAM and PI fluorescence using a BD 
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FACSCanto II flow cytometer (BD Biosciences, San Jose, CA). Only single cells 
were selected for analysis, and the analysis was preformed using FlowJo software 
(FLOWJO Inc., Ashland, OR). 
5.2.4. Antifungal activity assay 
In order to assess the antimicrobial activity of the peptides, a microdilution 
assay was performed. After subculturing cells and growing the culture to OD600=0.5, 
a 5×105 cells/mL cell suspension was prepared in 10 mM Na2HPO4. Serial dilutions 
(20 µL) of the peptides were prepared at 0.2 µM–100 µM in 96-well plates, and the 
cell suspension (20 µL) was then added into each well. A control well containing 50 
µM free FAM in 10 mM Na2HPO4 buffer was used as a control. The plate was 
incubated at 30 °C with vigorous shaking at 400 rpm for 60 min. Treated cells were 
diluted 20-fold in 10 mM Na2HPO4 buffer, and 100 µL of diluted cell suspension was 
added into 100 µL fresh YPD medium in a new 96-well plate. Plates were incubated 
at 30 °C with vigorous shaking for 16 hours, and the OD600 of the wells was measured 
using a 96-well plate reader (BioTek, Winooski, VT). The percentage of killing was 
calculated from  
Killing (%) = (1 −
OD600,peptide
OD600,control
)×100 (1)  
Minimal inhibitory concentrations were determined as the minimum 
concentration resulting in a 50% reduction in cell viability (MIC50). 
5.2.5. Membrane depolarization assay 
Membrane depolarization was evaluated using 3,3'-dipropylthiadi-
carbocyanine iodide (DiSC3(5)). Subcultured C. albicans cells were washed twice 
with 10 mM Na2HPO4 buffer and concentrated to a final OD600=1.0. DiSC3(5) 
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(ThermoFisher) was diluted to a stock concentration of 1 M. A Volume of 990 µL of 
cell suspension was added to a glass micro-cuvette, and the fluorescence emission 
was measured using a fluorometer (Molecular Devices; 633 nm excitation and 666 
emission filters). This concentrated cell suspension containing no peptide was used to 
measure the baseline fluorescence level for 60 sec with data collected every 3 sec. 
The DiSC3(5) stock solution (1 µL) was added into the suspension and the 
fluorescence was measured for another 120 sec until the reading reached a steady 
level. A volume of 1 µL of 50 g/L glucose stock solution was added into solution to 
further reduce the fluorescence level for another 120 sec. A volume of 10 uL of 
peptides solution was added into the solution and the fluorescence signal was 
measured for 600 sec. All experiments were performed with three replicates. 
5.2.6. Monte Carlo simulation 
To understand the main force field of peptide-membrane interaction, we used 
a Monte Carlo simulation model to simulate membrane binding for peptides with 
potential helical structures upon interactions. MC simulations of the peptides were 
performed using the MCPep server (available online at http://bental.tau.ac.il/MCPep/) 
[12]. The hydrophobicity of the membrane was represented as a smooth profile of 30 
Å width, similar to a fungal cell membrane [13], with the hydrophobic surface at a 
distance of 20 Å from the mid-plane. The negative charge was estimated based on the 
composition of C. albicans cell membranes [13], i.e., 20 % phosphatidylinositol + 17 
% (PS) + 3 % (PG) = 40% charged lipid. The solution was set with 0.01 M 
monovalent salts. The MC simulation was performed with 3 independent runs with 
500,000 MC cycles in each run. The total free energy of membrane association was 
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calculated as the difference between the free energies of the peptide in water and in 
the membrane. The average distance to the mid plane and the helical content 
percentage of each individual residue were simulated.  
5.2.7. Mammalian cells uptake and toxicity 
Human embryonic kidney cells (HEK293T) were purchased from ATCC 
(Manassas, VA, USA). Cells were cultured in media composed of Dulbecco’s 
Modified Eagle’s Medium with high glucose and L-glutamine (ThermoFisher, 
Waltham, MA, USA), 10% fetal bovine serum (FBS) (ThermoFisher), and 1% 
penicillin-streptomycin 10,000 U/mL (ThermoFisher). Cells were passaged at 70% to 
90% confluency. Cells were washed with phosphate-buffered saline (PBS; VWR, 
Radnor, PA, USA), and detached with 0.025% trypsin-ethylenediaminetetraacetic 
acid (EDTA, Invitrogen). All cells were cultured at 37 °C, 50% humidity, and 5% 
CO2:95% air. 
For evaluating the translocation efficacy of CPPs in mammalian cells and 
their effect on viability of mammalian cells, HEK293T cells were cultured in a 12-
well tissue culture treated polystyrene plate, such that cells were 90% to 100% 
confluent for the translocation experiment. Culture media was changed to FBS-free 
media the night prior to the uptake experiment. Cells were rinsed with PBS, then each 
well received 1 mL of peptide solution (10 μM) for experimental wells or 10 mM 
sodium phosphate buffer for control wells. Cells were incubated with the peptide 
solution or control buffer for 30 min at 37 °C. The peptide solution was subsequently 
removed, and cells were washed with PBS. Next, 0.25% trypsin-EDTA was added to 
each well, and cells were incubated for 5 min at 37 °C to facilitate cell detachment 
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from the well and peptide detachment from the cells. Cells were then washed with 
PBS, resuspended in 250 μL of PBS, and transferred to the respective flow cytometer 
tubes, with 1 μL of 1 mg/ml propidium iodide added right before sample testing. 
5.3. Results 
5.3.1. Quantification of translocation 
To study the effect of the charge and hydrophobicity of CPPs on translocation, 
we designed new peptides by systematically varying the amino acids to change the 
properties of the peptides (Table 5.1). All peptides were commercially synthesized 
with an N-terminal FAM fluorescent label, serving as the intracellular reporter and 
vacuolar localization indicator [8].  
To evaluate the translocation efficacy and localization pattern with 
C. albicans, we incubated cells with each of the peptides and quantified the 
translocation using flow cytometry (Figure 5.1). Compared with the parent peptides, 
the derivatives with a higher net charge (+2 higher) had a stronger translocation 
efficacy (pVEC 1, SynB 1, SynB 2 and SynB 8). pVEC 2, pVEC 3, SynB 3 and SynB 
4, which have a lower net charge (-2 lower), showed reduced cellular uptake or even 
complete loss of penetration for SynB 3. Meanwhile, altering the hydrophobicity of 
peptides did not significantly affect the cellular entry efficacy (pVEC 4-6 and SynB 
5-7). By combining the higher net charge and reduced hydrophobicity, we were still 
able to achieve an enhanced translocation (SynB 8). These results suggest that net 







Figure 5.1 Quantification of cellular location of CPPs in C. albicans. Cells were incubated 
with serial dilutions of peptide (1-50 µM) at 30 °C for 1 h, washed with trypsin, and 
incubated with CellTracker Blue vacuolar stain at room temperature for 10 min. Flow 
cytometry data were collected for FAM (peptide) fluorescence and vacuolar stain 
fluorescence. The percentage of cells with FAM fluorescence and with both FAM and 
vacuolar fluorescence were quantified. Error bars represent the standard error of the mean 




In addition, we also evaluated whether these changes were due to the amino 
acids changes or to the specific location of the modifications. Except SynB 3 and  
SynB4, the derivatives with same amino acid mutations but at different locations did 
not show a significant change in the behavior of peptides (for example, compare 
pVEC 2/pVEC 3 or SynB 1/SynB 2). The complete loss of translocation of SynB 3 
might be due to loss of a critical residue, as the RS modifications did not cause a 
loss of efficacy for the SynB 4 variant.  
5.3.2. Translocation mechanism 
Our translocation study not only quantified the effects of modifications on the 
efficacy of translocation, but also revealed the effect of these changes on the 
translocation mechanism. As our previous studied suggested, FAM and yeast 
vacuolar stains can be used to evaluate the uptake mechanism as yeast vacuoles are 
involved in the cellular trafficking process [8]. The higher extent of cytosolic peptide 
at low concentration is consistent with a higher degree of direct translocation, and 
endocytosis is more involved for peptides trafficked through vacuoles. Peptides 
appeared to be present more in the cytosol when the surface net charges were 
increased (pVEC 1, SynB 1, SynB 2, and SynB 8, Figure 5.1). A slightly stronger 
cytosolic tendency was observed for derivatives with a higher hydrophobicity 
(pVEC4, SynB 5 and SynB 6). By reducing the net charge or the hydrophobicity, we 
were able to observe more intracellular trafficking through vacuoles for both groups 
of peptides. When we combined the high net charge and reduction of hydrophobicity, 
we were able to achieve high uptake efficacy and a high level of vacuolar trafficking 
(correlated to low toxicity towards C. albicans as discussed in Chapter 3) with the 
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same peptide (SynB 8). Most importantly, our work suggests that we can alter the 
translocation mechanisms by changing the properties of peptides. The parent SynB 
has a higher tendency of translocation through vacuoles indicating an endocytic 
translocation, but the extra net charge led to data more consistent with direct 
 
Figure 5.2 CPP translocation into C. albicans under conditions that inhibit energy-
dependent endocytosis. Cells were incubated with peptides (10 µM) for 1 h. Control 
samples were incubated at 30 °C. Endocytosis was inhibited by adding 25 mM NaN3 or 
by changing the incubation temperature to 4 °C. The percentage of cells exhibiting FAM 
fluorescence was quantified by flow cytometry. Error bars represent the standard error of 




translocation related process at low concentration, where more cytosolic peptide was 
detected.  
 To further confirm our observation, we studied endocytosis of the peptides at 
low temperature and in the presence of NaN3, conditions that inhibit energy-
dependent endocytosis (Figure 5.2). The parent pVEC peptide used an energy- 
independent process to penetrate into cells, where the uptake of SynB was energy 
dependent. A higher net charge (pVEC 1, SynB 1, SynB 2, and SynB 8) maintained 
the translocation efficacy under ATP-inhibition conditions, indicating energy-
independent translocation. A similar effect was observed as we increased the number 
of hydrophobic residues of the peptides (pVEC 4, SynB 5 and SynB 6). Reduced 
charge or hydrophobicity resulted in a more energy-dependent mechanism. Our 
localization and endocytosis studies together helps us to understand how the 
properties of peptides affect and change the translocation mechanisms. 
In addition to endocytosis, direct translocation, which would potentially affect 
the membrane integrity, has been widely proposed as an uptake mechanisms for many 
CPPs. To evaluate whether membrane destabilization plays a role in translocation of 
the peptides in our study, we used PI and DiSC3(5) to identify pore formation in the 
membranes during CPP translocation into C. albicans (Figure 5.3). Overall, pVEC 
affected the membrane integrity more significantly than SynB for all peptide variants. 
pVEC has been proposed to enter the cells partially via direct translocation [8], while 
SynB entered cells through endocytosis (Chapter 3). Reducing charge and 
hydrophobicity significantly reduced the membrane damage for both peptides, except 
pVEC 3 showed moderate membrane depolarization at early time points (Figure 5.3 
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C). The charge played a more important role in membrane damage, as the derivatives 
with higher charge always showed a higher PI permeability and depolarized 
membrane potential, and the extra charge overcame the effect from the reduction of 
 
 
Figure 5.3 Effect of CPPs on integrity of cell membrane. Flow cytometry data indicating 
the percentage of cells with CPP translocation (FAM fluorescence) and with PI uptake in 
C. albicans in the presence of 10 µM pVEC/pVEC derivatives (A) or SynB/SynB 
derivatives (B). Membrane depolarization was evaluated by the release of DiSC3(5) into 
the solution and the increment of the fluorescence. At 60 sec, DiSC3(5) probe was added 
into cell suspension and reference fluorescence level was measured after 90 sec. At 180 
sec,10% glucose was added to further reduce the background. A volume of 10 µL of 1 
mM stock solution of pVEC peptides (C) and SynB peptides (D) was added to evaluate 
the fluorescence release due to the membrane depolarization. For (A) and (B), error bars 
represent the standard error of the mean for three separate experiments (N=3). For (C) and 
(D), each data point represents the average of three replicates with lines of a lighter shade 




hydrophobicity (SynB 7 vs. SynB 8). However, reducing hydrophobicity could 
potentially reduce the membrane damage, as deep interaction with the bilayer core 
may be more limited (pVEC vs. pVEC 6, and SynB 3 vs. SynB 8).  
5.3.3. Antifungal activity 
The PI stain could potentially indicate cell death due to a permeabilized 
membrane. Thus, our observation of propidium iodide permeability (Figure 5.3) 
could indicate that the CPP derivatives kill fungal cells. To examine the toxicity of 
CPPs toward C. albicans, we incubated the cells with serial dilutions of the peptides. 
At high concentrations of peptide, we observed significant toxicity for all peptides 
(Figure 5.4). For the peptides with more cytosolic localization (Figure 5.1) and more 
PI permeability (Figure 5.3), which includes those with a higher net 
charge/hydrophobicity (pVEC1, pVEC 4, SynB 1, SynB 2, and SynB 8), the 
 
 
Figure 5.4 Toxicity of CPPs and the derivatives toward C. albicans. Cells were incubated 
with serial dilutions of peptides (0.2-100 µM) for 1 h at 30 °C. Samples were diluted, 
mixed with YPD medium, and incubated at 30 °C for 16 h. Optical density (OD600) of the 
cultures was measured and converted to killing percentage. Error bars represent the 




antifungal activity was higher than for the ones with a lower net 
charge/hydrophobicity. The net charge has a higher impact on toxicity than 
hydrophobicity, as the derivatives with different charges always showed more 
significant changes in the antifungal activities compared to those with altered 
hydrophobicity.  
Our antifungal activity assays can also serve as a gauge to evaluate the effect 
of peptide properties on the activities. By tuning the charge and hydrophobicity of the 
peptides, we can design peptides with stronger or weaker antifungal activities.  
5.3.4. Simulations of peptide-membrane interactions 
To gain insight into the membrane association process for the peptides, we 
used a Monte Carlo simulation to understand the peptide-membrane interactions at 
the molecular level [12]. This model is dedicated to simulation of peptides with 
potential α-helical conformations upon membrane binding and insertion.  Although 
the data in in Chapter 4 suggests that the parent SynB does not form a helical 
structure while interacting with cells and membranes, we still included the SynB 
derivatives in these studies to explore potential shifts in the biophysical 
characteristics of SynB derivatives. 
The free energy calculation provided a detailed analysis of the membrane 
association process (Table 5.2). For all peptides, the membrane association was 
thermodynamically favorable, as indicated by the negative free energy for the 
peptides in solution to bind the membrane (ΔGTotal). The major contribution to the 
membrane association was always the electrostatic force (ΔGcoul) due to the opposite 

























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































peptides increased, this electrostatic force was stronger, such as was seen for pVEC 1, 
SynB 1, SynB 2, and SynB 8. Peptides with a lower net charge exhibited a lower 
electrostatic force contribution, including pVEC 2, pVEC 3, SynB 3 and SynB 4. The 
energy for membrane association was lowest for SynB 3, which showed almost no 
intracellular uptake. The hydrophobicity did not significantly affect this energy 
contribution. Compared to SynB, the derivatives SynB 1, SynB 2, and SynB 8 
showed significant free energy for conformational transition, indicating structural 
shift upon membrane association. These calculations show that the electrostatic force 
plays a strong role in membrane association, so changing the charge of a peptide has 
an impact on this membrane association. However, these results must be viewed vary 
Table 5.2 Membrane association free energy calculation from Monte Carlo simulation 
Peptides ΔGTotala (kT) ΔGconfb (kT) ΔGSILc (kT) ΔGcould (kT) ΔGdefe (kT) 
pVEC -28.58 -2.09 -9.95 -16.79 0.25 
pVEC 1 (+2) -32.95 -4.55 -9.73 -22.56 0.25 
pVEC 2 (-2) -26.77 -3.04 -9.84 -13.85 0.26 
pVEC 3 (-2) -26.84 -3.33 -9.93 -13.82 0.25 
pVEC 4 (+Hyb) -32.59 -2.98 -12.29 -17.67 0.25 
pVEC 5 (-Hyb) -29.20 -2.86 -9.74 -16.84 0.25 
pVEC 6 (-Hyb) -14.54 0.02 0.59 -15.41 0.25 
SynB  -13.65 0.17 0.66 -14.75 0.26 
SynB 1 (+2) -21.81 -1.74 0.54 -20.85 0.25 
SynB 2 (+2) -21.48 -1.74 0.81 -20.76 0.25 
SynB 3 (-2) -8.81 0.09 0.47 -9.63 0.25 
SynB 4 (-2) -9.06 -0.57 0.36 -9.11 0.26 
SynB 5 (+Hyb) -14.27 0.36 0.27 -15.15 0.26 
SynB 6 (+Hyb) -17.57 0.26 -1.58 -15.81 0.25 
SynB 7 (-Hyb) -13.72 -0.45 1.08 -14.60 0.25 
SynB 8  
(+2/-Hyb) 
-19.4 -0.72 1.40 -20.32 0.25 
a. ΔGTotal, total free energy difference between the peptide in solution and with the membrane 
b. ΔGconf, free energy change due to membrane-induced conformational changes in the peptide 
c. ΔGSIL, free energy change due to the hydrophobic interaction with the core of bilayer 
d. ΔGcoul, free energy change due to the electrostatic interactions between titratable residues of 
the peptide and membrane surface charge 




cautiously, as the experimental secondary structure for the derivatives have not been 
determined and the MC simulations are only intended to be used for helical peptides. 
Previous mechanistic studies in Chapter 3 suggested that pVEC enters cells 
via direct translocation and macropinocytosis and that the translocation of SynB is 
endocytosis-related [8]. In Chapter 4, I correlated the translocation with MC 
simulation, showing how free energy calculation can be used to explain and predict 
the translocation mode. The negative value of ΔGconf and ΔGSIL (representing free 
energy due to membrane association induced conformation changes and free energy 
due to hydrophobic interactions, respectively) along with the PI stain assay and 
endocytosis assay, could indicate deeper membrane interaction and membrane 
disruption. Except pVEC 6, all pVEC derivatives showed negative values for these 
two types of energy. As discussed above, pVEC peptides other than pVEC 6  
also showed higher PI permeability (Figure 5.3 A), whereas pVEC 6 exhibited little 
intracellular PI staining. For SynB, none of the peptides showed significant negative 
values for structural transition and hydrophobic interaction, consistent with an 
endocytosis-dependent translocation and our experimental studies of endocytosis and 
membrane permeabilization (Figures 5.2 and 5.3). Importantly, the hydrophobicity 
of the peptides affected the value of ΔGconf and ΔGSIL more significantly than the 
charges, suggesting the deeper membrane interaction and translocation mechanism 
are more directly related to the hydrophobicity of the peptides.  
To further investigate the peptide-membrane interaction and trans-membrane 
processes for the pVEC derivatives, we also used MC simulation to predict the 
peptide location in relation to the membrane bilayer (Figure 5.5 and 5.6). For pVEC 
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and the derivatives other than pVEC 6, all the peptides showed a partial insertion into 
the membrane. The inserted portion exhibited a higher helical content percentage, 
indicating a stronger tendency of forming an α-helical structure (Figure 5.5). This 
insertion can also be explained by our calculations from the simulations, as they 
showed a higher energy for structural transition and hydrophobic interaction (ΔGconf 
and ΔGSIL, Table 5.2). In contrast, pVEC 6 had a lower calculated energy of ΔGconf 
and ΔGSIL, the membrane insertion could no longer be observed and the helical 
content percentage was much lower.  
For SynB and its derivatives, no significant free energy for conformational 
change and hydrophobic interaction was observed in our calculation, and we did not 
see significant membrane insertion for any peptides (Figure 5.6). Peptides with higher 
net charges or higher hydrophobicity showed ΔGTotal and closer interaction with the 
hydrophobic interface, including SynB 1, SynB 2, SynB 5 and SynB 6 (Figure 5.6). 
These peptides showed energy-independent translocation mechanisms (Figure 5.2) 
and high PI permeability (Figure 5.3 B). Although no significant helical structures 
were observed for any SynB peptides, these results can still aid the understanding of 
the relationship between the secondary structure of the peptides, the properties of the 
peptides, and the translocation mechanism.  Obtaining experimental data on the 
secondary structures of the SynB derivatives will provide additional data and 
determine the level of trust that can be placed in these simulations. 
5.3.5. Mammalian cell study  
 Our ultimate goal is to design optimal CPPs that can be applied to treat fungal 
infections. I observed toxicity towards fungal cells in this study, yet the effects on 
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mammalian cell viability are also important. I evaluated the translocation of the CPPs 
into the mammalian cell line, HEK293T, as well as the effect of the CPPs on the 
viability of the mammalian cells (Figure 5.7). All peptides showed significant 
translocation at 10 µM, even SynB3, which completely lost the ability to translocate 
 
Figure 5.7 Evaluation of the translocation and cytotoxicity of CPPs and their derivatives 
towards HEK293T. A total count of 2 × 105 of cells were seeded and put into serum-free 
media a day for experiment. Cells were treated with 10 mM sodium phosphate buffer 
(Control) or 10 μM of peptide solution in 10 mM sodium buffer for 30 min at 37°C. Cells 
were carefully washed and trypsin treated to remove surface bounded peptides. PI was 
added prior to the flow cytometry measurement of the percentage of FAM-positive cells 
and the ones with PI uptake among these cells. Error bars represent the standard error of 
the mean for three separate experiments (N=3). 
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into fungal cells. More importantly, although a high net charge or high 
hydrophobicity significantly enhanced the cytotoxicity towards C. albicans, we did 
not observe any viability loss for mammalian cells with any of the peptides. Our 
modification of CPPs did not directly affect the viability of mammalian cells, 
indicating the specificity of the peptides between two types of cells in terms of 
toxicity.  
5.4. Discussion 
Cell penetrating peptides (CPPs) have great potential in drug delivery and 
therapeutic application. Currently, the majority of CPPs studies have been performed 
in mammalian cells, with limited understanding of their interaction with microbial 
cells. In addition, most of the CPPs in the previous studies did not show the cell 
specificity required for developing CPPs as disease-specific drug delivery methods. 
In this study, we used a rational design approach to correlate the properties of the 
CPPs to their function and translocation mechanisms. This enables us to understand 
the structure-function relationship of the CPPs. We can also use our experiments to 
investigate the peptide-cell interaction and the mode of action and to improve the 
specificity of CPPs by tuning the properties of the peptides.  
Since the peptides have an opposite charge compared to cell membranes, the 
net charge of peptides has been shown to play an important role in the translocation 
process of CPPs [3, 8, 14, 15]. We observed that a high net charge in CPPs strongly 
promoted intracellular delivery of the peptides. In addition to the higher translocation 
efficacy, it also led to a stronger tendency for cytosolic delivery (Figure 5.1) and a 
higher cytotoxicity (Figure 5.4). Direct translocation (Figure 5.2 and 5.3) and a 
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closer and stronger membrane interaction (Figure 5.5 and 5.6) is also associated with 
increased net charge. Our data indicate that a high net charge results in stronger 
membrane association and a more aggressive direct translocation mechanism, 
regardless of the original mode of action, as we modulated the translocation method 
of SynB from endocytosis to direct translocation by increasing the net charge.  
After membrane association, the next step of the membrane interaction is 
related to the hydrophobicity, as the core of the bilayer is hydrophobic. By tuning the 
hydrophobicity, we can also control the efficacy of the uptake and the translocation 
mechanisms. While the hydrophobicity did not significantly affect the translocation 
efficacy (Figure 5.1), the intracellular trafficking, translocation mechanism, and 
membrane insertion are closely related to the number of hydrophobic residues on the 
peptides. We reduced the hydrophobicity to achieve a more energy-dependent uptake 
mechanism, lower disruption of the membrane integrity, and a lower toxicity towards 
fungal cells. This will enable us to develop CPPs as a “safer” vehicle for delivering 
cargo with biological activity without damaging the host cells.  
To use CPPs as therapeutic tools for drug delivery or as antifungal agents, a 
low level of toxicity to mammalian cell lines is very important to ensure the safety of 
the treatment. We selected pVEC and SynB as peptides to study, because they have 
been reported to exhibit little effect on the viability of multiple mammalian cell lines 
[5, 6, 10, 16, 17]. Although we have observed significant toxicity towards fungal 
pathogens, we observed no significant loss of viability in HEK293T cells. This 
suggests that our newly engineered peptides can all be used for cargo delivery or to 
kill fungal cells without damaging mammalian cells that may also be present. 
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Interestingly, SynB 3, which showed no translocation into fungal cells, can 
significantly enter the mammalian cell line, indicating the strong specificity of this 
peptide and the impact of different membrane compositions on translocation into 
these two types of cells.  
5.5. Conclusion 
We have developed a series of novel CPPs based on two well-studied 
peptides. We were able to tune the translocation, toxicity, and mode of translocation 
by altering the net charge and hydrophobicity of the peptides. Our study provides data 
on the structure-function relationships for CPPs to improve understanding of the 
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Chapter 6. Effect of a flexible linker on recombinant 
expression of CPP fusion proteins and 
their translocation into fungal cells2 
6.1. Introduction 
Although CPPs are capable of carrying protein cargo into cells, the 
recombinant production of CPP fusions to protein cargo can be challenging. The 
CPP-cargo protein fusion can exhibit low levels of expression or be found in 
inclusion bodies when produced in Escherichia coli cells, as has been observed for 
fusions of various cargos to the TAT peptide and a poly-arginine peptide [1-5]. Even 
if fusions can be produced and purified, the CPP-cargo fusion production may be 
substantially lower than the cargo protein alone [6], the solubility of the fusion may 
not be sufficient in a biological buffer [7], or the fusion may not successfully enter 
cells [2]. Finding methods to improve the recombinant expression and solubility of 
CPP fusions will aid in the development of CPPs as vehicles for carrying protein 
cargo into cells. One approach to improving the production of peptide-protein fusions 
is to incorporate a flexible peptide linker between the peptide and its fusion partner. 
One commonly used flexible linker is the glycine-serine linker (G4S)n, which has 
                                                 
2 This chapter has been published in the Molecular Biotechnology Journal and appears in this thesis 
with the journal`s permission:  
Gong Z, Walls MT, Karley AN, Karlsson AJ 
Effect of a Flexible Linker on Recombinant Expression of Cell-Penetrating Peptide Fusion 
Proteins and Their Translocation into Fungal Cells.  
Mol Biotechnol. 2016 Dec;58(12):838-849. 
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been used to improve the expression of a number of proteins fusions [8-11]. (G4S)n 
linkers have also been used to improve the biological activity of antibody fragments, 
bifunctional enzymes, and many other proteins and protein fusions [12-17]. Although 
linkers have been used to enhance expression of many fusion constructs, their effect 
on expression of CPP fusions and on cellular uptake of CPPs, especially for fungal 
cells, has not been studied. 
To improve the understanding of the effect a (G4S) linker has on CPP 
expression, we genetically fused pVEC and NPFSD to green fluorescent protein 
(GFP) with and without the linker. We recombinantly produced the fusions 
containing each peptide in E. coli, purified the constructs, and evaluated their 
translocation into C. albicans cells. Our results show that the flexible linker improves 
the recombinant production of the CPP-GFP fusions, while having either a positive or 
neutral impact on uptake by the fungal cells. 
6.2. Materials and methods 
6.2.1. Plasmid construction 
Plasmids containing GFP and genetic fusions of NPFSD and pVEC to GFP 
were constructed using the pET21a(+) (Novagen) plasmid, which contains a C-
Table 6.1 Primers used in this chapter 


















terminal hexahistidine tag (6XHis). All primers are provided in Table 6.1. To 
construct the plasmid containing GFP only, the DNA encoding GFP was amplified by 
PCR from a template plasmid in our lab stock using the primers SacI-ATG-GFP-F 
and GFP-NotI-R and inserted between the SacI and NotI sites of pET21a(+), resulting 
in pET21-GFP. To construct the plasmids containing genetic fusions of GFP to the 
NPFSD peptide, the DNA encoding GFP with an N-terminal NPFSD peptide was 
amplified using a forward PCR primer containing the NPFSD sequence with or 
without a C-terminal G4S peptide linker (EcoRI-NPFSD-G4S-SacI-GFP-F and 
EcoRI-NPFSD-SacI-GFP-F, respectively) and the reverse primer GFP-NotI-R. The 
PCR products were then inserted between the EocRI and NotI sites of pET21a(+), 
resulting in pET21-NPFSD-G4S-GFP and pET21-NPFSD-GFP. Plasmids containing 
genetic fusions of pVEC to GFP were constructed using annealed primers. For 
pET21-pVEC-GFP, the primer pair pVEC-1-top and pVEC-1-bottom and the primer 
pair pVEC-2-top and pVEC-2-bottom were 5’ phosphorylated and then annealed to 
create the primer dimer pairs pVEC-1 and pVEC-2, respectively. The annealed 
pVEC1 had an EcoRI sticky end, and the annealed pVEC2 had a SacI sticky end; 
pVEC1 and pVEC2 also had complementary sticky ends, allowing them to anneal to 
each other. The two primer dimer pairs were then inserted between EcoRI and SacI of 
pET21-NPFSD to replace the DNA encoding NPFSD with the DNA encoding pVEC. 
Similarly, inserts constructed with the pVEC-G4S-2-top and pVEC-G4S-2-bottom 
primer pair and the pVEC-1-top and pVEC-1-bottom primer pair were inserted 
between EcoRI and SacI of pET21-NPFSD-GFP to generate pET21-pVEC-G4S-
GFP. All plasmids were sequenced to confirm the constructs were correct. 
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6.2.2. Protein expression and purification 
Plasmids containing the GFP and fusion protein constructs were transformed 
into E. coli BL21(DE3) electrocompetent cells for protein production. For most 
experiments, overnight cultures of BL21(DE3) cells were subcultured into fresh 
Luria-Bertani (LB) medium with ampicillin (100 µg/ml) at an optical density of 
OD600=0.05 and grown at 37 °C for 3 h while shaking at 225 rpm. Expression was 
then induced by adding 0.05 mM isopropyl β D 1 thiogalactopyranoside (IPTG, 
Fisher BioReagents), and the cultures were shaken at 37 °C for an additional 8 h. 
Cells were then pelleted by centrifugation at 4,300× g for 15 min and lysed with 
BugBuster Master Mix (EMD Millipore) following the manufacturer’s protocol. 
Following centrifugation of the whole cell lysate at 11,000× g for 40 min at 4 °C, the 
supernatant was taken as the soluble fraction. For the experiments to evaluate protein 
expression at different induction conditions, analogous procedures were followed, 
except the induction of expression was done with different temperatures (20 °C, 30 
°C, and 37 °C), induction times (2 h, 4 h, and 8 h), and IPTG concentrations (0.05 
mM, 0.1 mM, and 0.5 mM).  
The GFP and CPP-GFP fusions were purified from the soluble fraction of the 
cell lysate using immobilized metal affinity chromatography (IMAC). The soluble 
fractions of the lysates were passed through a 0.2 μm filter and applied to an IMAC 
Profinity column (Bio-Rad) attached to an NGC liquid chromatography system (Bio-
Rad) to bind the C-terminal 6XHis tag to the column. Proteins were eluted in a buffer 
containing 300 mM KCl, 30 mM KH2SO4 and 500 mM imidazole. The eluate was 
dialyzed against 20 mM imidazole and applied to an Enrich-Q anion-exchange 
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column (Bio-Rad). The CPP-GFP fusion proteins were eluted from the anion-
exchange column by increasing the concentration of NaCl in a stepwise manner from 
250 mM to 400 mM. The purified proteins were stored at 4 °C after dialysis against 
0.1× PBS. The concentration of each protein was measured on a NanoDrop 
instrument (Thermo Scientific) using the ε/1000 method, which measures the 
absorbance at 280 nm and uses Beer’s Law to determine the molar concentration. The 
extinction coefficient (ε) for each protein was estimated based on the amino acid 
sequence using the ProtParam tool on the ExPASy website [18]. For quantifying the 
yield of purified protein, three biological replicates (three separate cultures) were 
prepared on separate days. Protein yields were compared with a paired t-test using a 
p-value of p<0.1 as significant. 
Western blotting and SDS-PAGE were used to evaluate protein expression 
and purity. Western blotting was used to compare the amount of the protein 
constructs present in the crude soluble cell lysates. Samples were normalized by 
culture volume and separated on Any kD Mini-PROTEAN TGX gels (Bio-Rad). 
After transferring to a polyvinyl difluoride (PVDF) membrane, the GFP and CPP-
GFP fusions were detected using an anti-GFP (Mouse) primary antibody (Abcam) 
and a horseradish peroxidase (HRP)-conjugated anti-mouse (Rabbit) secondary 
antibody (Abcam). The blot was incubated with Clarity Western ECL substrate (Bio-
Rad), and chemiluminescence was imaged on a ChemiDoc MP documentation system 
(Bio-Rad). To follow the progress of the purification, the elution fractions from the 
IMAC and ion-exchange columns were normalized by volume and separated on Any 
kD Mini-PROTEAN TGX gels (Bio-Rad). The proteins were then stained with Bio-
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Safe Coomassie stain (Bio-Rad) and imaged. The purity of the proteins was assessed 
from images of the Coomassie-stained gels using densitometry analysis in ImageLab 
software (Bio-Rad). Images were taken for each batch of purification (three 
replicates), and results were similar in each case. 
6.2.3. Strains and culture conditions 
C. albicans strain SC5314 (American Type Culture Collection) was first 
inoculated from yeast-peptone-dextrose (YPD) agar (1% yeast extract, 2% peptone, 
2% glucose, and 2% agar) into 5 mL of fresh YPD medium (1% yeast extract, 2% 
peptone and 2% glucose) and grown overnight at 30 °C while shaking at 230 rpm. 
The cells in the overnight culture were subcultured into 25 mL of fresh YPD medium 
with an OD600=0.1 (about 2×10
6 CFU/mL). The culture was then grown at 30 °C to 
OD600=0.5 (about 1×10
7 CFU/mL) while shaking. Cells were harvested by 
centrifugation at 4,000 g for 15 min at 4 °C and washed twice with 0.1× PBS. 
6.2.4. Cellular uptake analysis by fluorescence imaging 
Translocation of CPP-GFP constructs was analyzed using fluorescence 
microscopy. A total of 5×105 C. albicans cells in 100 µL of 0.1× PBS was prepared 
as described above. For each GFP or CPP-GFP construct, 100 µL of a 1.0 µM protein 
solution in 0.1× PBS was prepared. The cell suspension and protein solution were 
mixed and incubated at 30 °C with vigorous shaking for 10 or 60 min. Cells were 
collected by centrifugation at 4,500× g for 10 min at 4 °C and washed twice with 0.1× 
PBS. The cell pellet was then incubated with 200 µL of 0.025% trypsin (Invitrogen) 
at 37 °C for 5 min to remove surface-bound protein [19]. After trypsin treatment, 
cells were again washed with 0.1× PBS and resuspended in 10 µL of 0.1× PBS. An 
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aliquot of 5 µL of the cell suspension was transferred to a glass slide and imaged 
using an Olympus IX83 fluorescence microscopy system. Differential interference 
contrast (DIC) and GFP fluorescence images were taken using the automatic process 
manager of the CellSens Dimension software (Olympus), and images were analyzed 
using NIH ImageJ software [20]. Cells in the DIC and GFP images were counted 
separately to quantify the percentage of cells with GFP uptake. For each of three 
biological replicates, three DIC and three GFP images were taken to determine a 
percentage of cells with uptake for each replicate. Statistical comparisons of uptake 
data were performed using t-tests with a 90% confidence level.  
6.2.5. Cell viability 
To evaluate the toxicity of the CPP-GFP constructs towards C. albicans, the 
viability of C. albicans following incubation with the fusion proteins was measured. 
GFP and CPP fusions to GFP were prepared as serial dilutions (0-5 µM) in 0.1× PBS, 
with a final volume of 100 µL. Control wells containing 100 µL of 10 µg/µL 
nourseothricin (NTC; Jena Bioscience) in 0.1× PBS and 100 µL of 0.1× PBS alone 
were included as controls for complete inhibition of viability and no inhibition of 
viability, respectively. An overnight culture of C. albicans was diluted to OD600=0.1 
with YPD medium, and 100 µL of the cell suspension was added to each well. The 
plate was incubated at 30 °C with vigorous shaking. The OD600 of the wells was 
measured every 2 h for 8 h using a microplate reader (Bio-Tek). Replicates of the 




6.3.1. Expression and purification of fusion constructs 
In order to better understand the interaction of CPPs with C. albicans, we 
chose to study two CPPs previously shown to enter C. albicans, NPFSD and pVEC. 
The proposed mechanism of entry for these peptides is different, along with their 
physical properties. pVEC is a highly positively charged peptide that enters cells 
through a non-endocytic process [21]. NPFSD is a slightly negatively charged peptide 
that is proposed to enter cells via clathrin-mediated endocytosis [22]. Our goal was to 
evaluate the recombinant production and cell-penetration of the two peptides as 
genetic fusions to GFP with and without a flexible peptide linker separating the CPP 
and cargo. GFP is an ideal choice of protein cargo for the CPPs, because its 
fluorescence makes detection of translocation straightforward by fluorescence 
microscopy and because it is easily expressed recombinantly in E. coli [23]. We 
chose a linker composed of glycine and serine residues (G4S), because a G4S linker 
  
Figure 6.1 Genetic constructs used to produce CPP-GFP fusion proteins. CPPs 
were fused to GFP, with or without a glycine-serine (G4S) linker 
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has been widely used to increase production and stability of recombinant proteins in 
E. coli [24-28].  
To study the effect of the linker on expression of CPP-cargo protein fusions, 
we separately fused the DNA encoding each of the CPPs (NPFSD and pVEC) to the 
DNA encoding GFP with and without the G4S linker between the CPP and GFP 
(Figure 6.1). We expressed the proteins in E. coli BL21(DE3) cells and compared the 
expression of each of the protein constructs (Figure 6.2). The expression of GFP 
without fusion to a CPP was much higher than the expression of the CPP-GFP 
   
Figure 6.2 Expression of fusion proteins. CPP fusions to GFP were expressed in 
BL21(DE3) cells at 37 C for 8 h with 0.05 mM IPTG. The soluble cell lysates and 
insoluble fractions were analyzed by Western blotting, with samples normalized by culture 
volume. The Western blot was probed using an anti-GFP (mouse) primary antibody and an 
HRP-conjugated anti-mouse secondary antibody. The soluble and insoluble fractions were 
imaged simultaneously on the same Western blot. GroEL (60 kDa) was used as an internal 
loading control and was probed by an anti-GroEL (rabbit) primary antibody and an HRP-
conjugated anti-rabbit secondary antibody 
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fusions, indicating that the CPPs substantially reduce the amount of soluble GFP 
produced in E. coli, as reported previously for CPP-cargo protein fusions [29]. The 
reduction in expression was more pronounced for the pVEC constructs than for the 
NPFSD constructs, potentially due to the antimicrobial activity of the pVEC peptide, 
which has been shown previously to kill E. coli cells [30]. Importantly, for both 
peptides, the addition of the G4S linker between the CPP and GFP clearly increased 
the expression level of the protein fusions. This was a consistent phenomenon for 
Figure 6.3 Expression of CPP–GFP fusion proteins under different induction conditions 
and in different strains. A The effect of temperature was evaluated by inducing expression 
at 20, 30, and 37 C for 8 h with 0.1 mM IPTG. B The effect of induction time was 
evaluated by inducing expression at 37 C for 2, 4, and 8 h with 0.1 mM IPTG. C The 
effect of inducer concentration was evaluated by inducing expression at 37 C for 8 h at 
0.05, 0.1, and 0.5 mM IPTG. D To compare expression in BL21(DE3) and Rosetta(DE3) 
strains, cultures were induced at 37 C for 8 h with 0.05 mM IPTG 
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these constructs under various expression conditions (Figure 6.3). While temperature 
and induction time did have some effect on expression, these effects varied between 
the constructs, and the linker improved expression of the fusion proteins under all 
conditions. The linker provides a more robust method to enhance the expression of 
the CPP fusions to cargo proteins than varying expression conditions.  
We purified the fusion proteins to quantify the effect of the linker on yields of 
purified protein and better gauge the impact of the linker. The proteins were first 
purified via their C-terminal 6XHis tag using an IMAC column. Following IMAC, all 
protein constructs still contained substantial impurities (Figure 6.4). For the CPP-
fused constructs, the Coomassie staining shows that the impurities were more 
Figure 6.4 Purification of fusion proteins. Coomassie staining was used to evaluate the 
purification progress and the purity of the fusion proteins. The crude soluble lysates, 
resolubilized insoluble fractions, and elutions from immobilized metal affinity (MA) 
chromatography and anion-exchange (IE) chromatography are shown. The expected sizes 
of the proteins are 27.9 kDa for GFP, 29.0 kDa for NPFSDGFP, 29.3 kDa for NPFSD-
G4S-GFP, 30.1 kDa for pVEC-GFP, and 30.4 kDa for pVEC-G4S-GFP. These data are 
intended to illustrate the quality of the purification and should not be compared for yield 
of the proteins (yields are found in Table 6.2) 
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abundant than the desired protein constructs. Hence, we performed ion-exchange 
chromatography with an anion-exchange resin to further purify each of the proteins. 
The purity of each protein was above 90% following anion-exchange chromatography 
(Figure 6.4, Table 6.2). Consistent with the difference in expression, GFP with no 
CPP was purified with a much higher yield than the CPP fusions, and a higher yield 
of protein was obtained for the NPFSD constructs than for the pVEC constructs. 
Likewise, the addition of the linker to the CPP-GFP constructs led to an increase in 
the purified protein yield, with an increase of 24.5% for the NPFSD fusion (p=0.003) 
and an increase of 50.0% for the pVEC fusion (p=0.086). Although the linker was not 
able to recover the level of purified protein to the level of GFP alone, it did produce a 
significant improvement in yield, which will be beneficial when producing CPP 
fusions for future experiments.  
Table 6.2 Purification yield of different CPP-GFP fusion proteins 
Protein Yield (mg protein/L of culture)a Purity (%)a 
GFP 0.795±0.093 97.0±1.5 
NPFSD-GFP 0.212±0.013 92.4±5.6 
NPFSD-G4S-GFP 0.264±0.013 95.2±1.5 
pVEC-GFP 0.106±0.013 98.4±1.6 
pVEC-G4S-GFP 0.159±0.053 97.2±2.6 






* The average was calculated from three individual replicates 
with the standard deviation 
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6.3.2. Cellular uptake efficiency of fusion proteins 
As previous research has shown, NPFSD and pVEC have the capacity to 
translocate into C. albicans cells [31, 32]. After showing that the G4S linker enhanced 
the recombinant expression of CPP-GFP fusions in E. coli, we next evaluated whether 
the linker affected this translocation. Cells were incubated with 0.5 µM of each 
protein construct for 10 min, treated briefly with trypsin to remove any fluorescent 
protein bound to the cell surface, and then examined by fluorescence microscopy to 
detect GFP. All four fusion proteins were observed intracellularly, whereas GFP 
lacking a CPP and a negative control with only PBS exhibited almost no fluorescent 
Figure 6.5 Cellular uptake of CPP fusions. A Microscopy images of C. albicans cells 
after incubation with fusion proteins for 10 min. Scale bar is 20 µm. B Uptake efficiency 
of CPP fusions (final concentration of 0.5 µM) after 10 min of incubation with cells. C 
Uptake efficiency of CPP fusions (final concentration of 0.5 µM) after 60 min of 
incubation with cells. For b and c, the number of cells in DIC and GFP images was 
counted separately after the indicated incubation time to calculate the percentage of GFP-
positive cells. Error bars represent the standard error of three separate experiments. 
Statistical significance was analyzed with a one-way ANOVA test (a = 0.1), and the 
number of asterisks indicates the level of significance (* for p ≤ 0.05, ** for p ≤ 0.01, and 
*** for p ≤ 0.001) 
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cells (Figure 6.5A). The GFP constructs were found in the cytoplasm of the cells 
under the conditions we evaluated, with no difference in the localization observed 
based on the CPP or on the presence of the linker. These results were confirmed by 
quantifying the percentage of fluorescence-positive cells (Figure 6.5B). The low 
level of positive cells in the samples with GFP and with no protein is at least partially 
explained by autofluorescence, which has been observed in yeast previously [33]. It is 
also possible that a small amount of GFP can be taken into the cells, even in the 
absence of a CPP. However, samples treated with the four fusion proteins for 10 min 
had significantly more GFP-positive cells than the samples with PBS only or GFP 
with no CPP. Translocation of NPFSD-GFP led to 1.2 times as many GFP-positive 
cells compared to GFP only, while translocation of pVEC-GFP led to 3.0 times as 
many GFP-positive cells. For constructs containing the NPFSD peptide, the addition 
of the G4S linker led to an improvement of translocation, with the NPFSD-G4S-GFP 
protein leading to 58% more GFP-positive cells compared to the construct lacking the 
linker (p=0.093) and improving the translocation to a level similar to pVEC-GFP. In 
contrast, the linker had little effect on the fusion proteins containing pVEC, with no 
statistical difference between the levels of GFP-positive cells for pVEC-GFP and 
pVEC-G4S-GFP (p=0.70). These results indicate that the linker does not diminish the 
ability of a CPP-cargo fusion to penetrate cells and has the ability to actually improve 
the translocation.  
CPPs have been frequently shown to enter cells within 15 min, but longer 
times can lead to a higher number of cells showing uptake [21, 34]. To evaluate 
whether longer time periods also lead to improved translocation of our constructs, we 
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increased the incubation time with the CPP fusions from 10 min to 60 min. 
Microscopy showed the results at 60 min were qualitatively similar to results at 10 
min, with the translocated constructs found in the cytoplasm of the C. albicans cells 
(data not shown). The uptake of both NPFSD fusions was significantly higher for 60 
min of incubation compared to 10 min (34.5% for NPFSD, p=0.049; 23.9% for 
NPFSD-G4S-GFP, p=0.090) (Figure 6.5B and Figure 6.5C), while there was no 
significant increase for the pVEC fusions with additional time. After 60 min of 
incubation, we observed statistically similar uptake for all four of the CPP fusions. 
Our results suggest that pVEC enters cells at a higher rate than NPFSD, but that the 
difference in the translocation rate can be overcome by incubating the CPP constructs 
for a longer time. However, incubating for a longer time also increases the 
background fluorescence and non-CPP-mediated translocation of GFP, which may 
impact the incubation time. 
6.3.3. Cell viability after uptake 
The goal of using CPPs is to deliver cargo into cells, and the ability to deliver 
cargo without affecting the viability of cells would broaden the range of applications 
of CPPs in biological studies. To examine the cytotoxicity of the CPP-GFP fusions, 
we monitored the cell growth of C. albicans in the presence of the CPP fusions and 
compared this growth to the growth in the presence of GFP (Figure 6.6). Incubation 
of C. albicans cells with GFP at concentrations of up to 5 µM of GFP did not lead to 
a difference in viability compared to cells incubated with no protein (data not shown). 
We observed a very minor loss of viability for cells incubated with NPFSD and 
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pVEC constructs, which is apparent from viability ratios below one for most data 
points after 0 h. However, the loss of viability due to the CPP constructs is relatively 
consistent over the course of the experiment, in contrast to the data for the antifungal 
agent nourseothricin, which continues to see a viability reduction beyond 6 h and is 
known to constantly inhibit C. albicans growth [35]. Our results for the toxicity of the 
CPP constructs are consistent with previous work that showed no toxicity of NPFSD 
towards yeast cells [22]. pVEC has been shown to exhibit antimicrobial activity 
towards some fungal cells [36] , but not C. albicans (consistent with our results) and 
 
Figure 6.6 Viability of C. albicans cells incubated with fusions of CPPs to GFP. 
C. albicans strain SC5314 cells were incubated with the indicated concentrations of 
pVEC-GFP, pVEC-G4S-GFP, NPFSD-GFP, and NPFSD-G4S-GFP in YPD medium, and 
the OD600 was monitored over time. The data are plotted as the ratio of the cell density 
(OD600) for samples with each fusion protein to the OD600 for samples incubated with 
GFP at the same molar concentration for the same period of time. A control containing 5 
µg/µL nourseothricin (NTC), an antifungal agent, was included, and those data are shown 
relative to 5 µM GFP. Data represent the average of three replicates, and error bars show 
the standard error, which was propagated through the calculations 
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no toxicity to multiple mammalian cell lines [37]. The linker between the CPPs and 
GFP does not show an effect on the viability of cells incubated with the CPP fusions, 
indicating the linker can be included without adverse effects on cells. The relatively 
low toxicity of the CPP fusions overall indicates that these constructs could be used 
as tools for delivering cargo to cells and studying the biological impact of the cargo. 
6.4. Discussion 
Genetic fusion techniques allow the production of recombinant proteins 
containing different domains with different functions, for example a CPP for cell 
penetration and a cargo protein with an intracellular function. However, different 
domains of fusion proteins may interfere with each other, resulting in poor 
expression. Rachel et al. reported that when a polypeptide is directly fused to 
different fusion partners, some peptides decrease the solubility of the fusion proteins 
[1, 2, 38]. A flexible linker not only separates the different domains to allow better 
function of each domain, but it also helps to enhance the recombinant expression [10, 
11, 39-41]. In this study, we successfully increased the expression of CPPs fused to 
GFP by using a glycine-serine linker, leading to a higher yield of the purified fusion 
proteins for cellular assays. Although the CPP fusion proteins were still expressed at 
significantly lower levels than GFP without a CPP attached, the linker reliably 
improved expression of CPP fusions under a variety of different temperatures and 
induction times.  
More importantly, the presence of the linker did not negatively affect the 
function of either domain of the fusion proteins. The G4S linker enhanced the 
translocation of NPFSD-GFP fusions significantly, whereas the translocation capacity 
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of pVEC-GFP fusions was unaffected. This result may be due to the different 
mechanisms of uptake for the two peptides. Previous work reported that NPFSD is 
translocated into cells through clathrin-mediated endocytosis [22], while pVEC enters 
cells through macropinocytosis (a non-receptor-based mechanism) [21]. Clathrin-
mediated endocytosis is the process cells use to take up molecules targeting specific 
receptors. If the structure of an endocytosed peptide like NPFSD is affected by 
attachment to a cargo protein, the interaction with the receptor could potentially be 
changed, altering the translocation capacity of the peptide. Inclusion of the flexible 
linker as a spacer between NPFSD and GFP could prevent disruption of this 
interaction with the receptor, leading to improved translocation of the construct 
containing the linker compared to the construct without the linker. Comparing with 
clathrin-mediated endocytosis, macropinocytosis is not specific for the molecule 
being translocated. As pVEC is translocated by macropinocytosis, the uptake of 
pVEC may be less affected by any structural changes due to fusion to the cargo 
protein; thus, inclusion of a linker may not as significantly affect the uptake of pVEC 
constructs.  
CPPs are being explored as novel drug delivery vehicles for delivering various 
molecules intracellularly. In order to use CPPs to explore the biological function of 
cargo inside cells, cell viability will be important for CPP-mediated delivery systems. 
Previous studies suggested that pVEC could be considered a “safe” CPP, since it does 
not significantly affect the viability of mammalian cells [37, 42]. No cytotoxicity data 
for NPFSD had been reported prior to our work. We observed only a very small 
decrease in viability due to either pVEC or NPFSD, suggesting both pVEC and 
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NPFSD could serve as a delivery system for C. albicans cells when maintaining cell 
viability is important. Furthermore, the G4S linker did not affect cytotoxicity, so its 
benefits to expression and uptake can be obtained with no negative impact on cell 
viability. 
6.5. Conclusion 
Using a glycine-serine linker, we were able to improve the expression and 
purification of CPPs fused to GFP without negatively impacting the cellular uptake 
efficiency and without substantial cytotoxicity toward C. albicans. These results 
suggest that future studies with additional CPPs and cargo could benefit from the 
inclusion of a linker between the CPP and the cargo. Additionally, exploring 
additional linkers would provide further insight into the mechanism by which the 
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Chapter 7. Conclusion and future work 
In Chapter 3 and 4, we demonstrated that CPPs can be functional towards the 
fungal pathogen Candida. Our initial screening and biophysical characterization of 
CPPs with Candida cells help us to understand how and why peptide internalization 
occurs and how the structure of CPPs is related to the translocation mechanism. I 
further investigated the structure-function relationship by using rational design of 
peptides in Chapter 5. The charge and the hydrophobicity of the peptides directly 
affected the translocation efficacy, mode of action, as well as the toxicity of the 
peptides. In Chapter 6, we showed that we can use pVEC to deliver the protein cargo 
GFP into C. albicans, validating the idea of developing CPPs as cargo delivery 
vehicles for fungal cells. Our work has significant impact for understanding CPPs in 
fungal pathogens and provides the motivation for additional work to further explore 
the application of CPPs for cargo delivery into fungal pathogens. 
7.1. Intracellular delivery of antifungal agents by CPP 
In Chapter 3, 5 and 6, I used CPPs to deliver both a small molecule (FAM) 
and a larger biomolecule (GFP) into C. albicans, indicating the feasibility of using 
CPPs to deliver bioactive molecular cargos into Candida pathogens. Our goal is to 
use CPPs to resolve the challenges in treating fungal infections, thus delivering 
antifungal agents and enhancing therapeutic effects need to be explored.  
Fluconazole has been widely used as the first-line antifungal drugs to treat 






Figure 7.1 Azole drug resistance mechanisms of C. albicans. Figure from [2] 
 
Figure 7.2 Scheme of synthesis pathway for CPP-fluconazole. Peptide will be 
commercially synthesized with C-terminal azide modification and N-terminal FAM label. 




fluconazole enters the cells, blocking the synthesis of ergosterol by silencing the 
ERG11 gene. In order to maintain the inhibition of the ERG11 gene, a cross-
membrane azole gradient should be maintained. Hence, the dosage of the azole drug 
is often high to keep the azole concentration gradient high. However, this higher 
dosage and long-term treatment promote the development of drug resistance from C. 
albicans [2]. As more azole enters the cells, some drug can still the synthesis of 
ergosterol, but two major genes, CDR and MDR1, are upregulated, resulting in 
overexpression of two membrane proteins that actively pump fluconazole out of the 
cells and reduce the therapeutic effects (Figure 7.1 [2]). Therefore, developing a 
highly efficient, safe delivery methods such as CPP will eliminate the high-dosage, 
long-term treating requirement, and enable better translocation of azole drugs with 
clear internalization mechanisms. 
The challenge for using CPPs to deliver fluconazole is the way to conjugate 
drugs to the peptides without affecting the properties of both the delivery vehicle and 
the molecular cargo. One of the most powerful, yet gentle, bioconjugation reactions is  
the Huisgen cycloadditions reaction [4], known as “click chemistry”, which requires 
an azide and alkyne residue in the chemicals, and it allows us to covalently link CPPs 
to drugs. I could modify peptides with an N-terminal azide functional group and 
fluconazole with an alkyne functional group as fluconazole has been successfully 
modified with an alkyne moiety to allow bioconjugation [3] (Figure 7.2). Starting 
from 1,3-difluorobenzene (1), Pore et al. were able to synthesize 2-(2,4-
difluorophenyl)-1-(1H-1,2,4-triazol-1-yl)pent-4-yn-2-ol (3), which has the alkyne 
group. With the help of click chemistry, the compound (3) can be turned into an 
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active fluconazole-similar. Meanwhile, solid-phase synthesis of peptides allows us to 
modify the C-terminus of the peptides. Previous research has shown the modification 
of peptides with both azide and alkyne modification [5]. As I propose to have 
fluconazole modified with alkyne group, I could have the peptides commercially 
synthesized with C-terminally azide label and N-terminally 5-FAM label. As 
commonly used chemicals for synthesis of pharmaceutical drug candidates, 3-
aminopropyl azide (4) can be attached to the carboxyl group of the first amino acid 
attached to the solid-phase beads using a reductive amination reaction. Modified 
peptides (6) could be commercially synthesized and used to react with the compound 
(3) to get the final product (7). Previous study of conjugation of fluconazole showed 
similar antifungal activity to the native drug [3], so I expect the CPP-fluconazole 
complex would validate the idea of using CPPs for small-molecule cargo intracellular 
delivery. The final drug product could be purified by reverse phase liquid 
chromatography and checked by mass spectrometry. 
As observed in Chapter 3, 4, and 5, some CPPs can directly affect the viability 
of C. albicans while delivering cargos into cells, such as pVEC and penetratin. They 
have an MIC50 value lower than 2 µM, and they can lead to at least 50% 
internalization at 1.5 µM. Meanwhile, although the MIC50 of fluconazole varies 
between different isolates, the average MIC50 value is 0.5 mg/L [6], which equals to 
1.6 µM. If the conjugation does not affect the efficacy of the peptides and the drug 
effects, the effective concentration of the conjugates should not be higher than 1.5 
µM. In addition, I observed pore formation in C. albicans when treated with these 
peptides, which would promote the translocation of the conjugates. A synergistic 
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effect would reduce the MIC values and enhance the therapeutic efficacy of the new 
conjugates. In such way, I could reduce the overall dosage to prevent adaptive 
resistance due to the high-concentration induced pump activation.  
7.2. Enhanced in vitro CPP-protein fusion production 
Chemical synthesis of peptides can ensure the accuracy of the sequence and 
allow many kinds of chemical medication. However, it has some disadvantages such 
as the high cost and the long processing time. Alternatively, peptides can be produced 
by biological systems. I demonstrated I can use recombinant expression technology to 
product CPP-GFP fusion proteins with the ability to translocate (Chapter 6). Due to 
the potential toxicity of the peptides, the overall recombinant expression yield is 
significantly lower than the cargo protein without CPPs. Innovative expression and 
production methods beyond the limitation of live cells need to be widely explored to 
increase the yield and efficiency of CPP-cargo fusion protein production. 
7.2.1. Cell-free protein synthesis 
The idea of using bacteria or yeast to produce recombinant proteins depends 
on the biological machinery inside cells. Cells have all the required enzymes to 
convert DNA into mature protein based on the central dogma. To remove the 
constraint of the cell membrane and the toxicity of the protein to the host cells, an in 
vitro new protein synthesis method, cell-free protein synthesis (CFPS) was 
developed. CFPS uses extracts from cells. The recovered cell extracts along with 
other essential components can be added into a tube to allow the direct access and 
control of the expression process. These essential components of 
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CFPS processes includes ATP, amino acids, salts, and template DNA (Figure 7.3 [7]).  
In recent decades, CFPS have been widely used to produce proteins from either 
plasmid DNA or DNA fragments (PCR products). Meanwhile, the extracted cell 
extracts can be lyophilized and stored, which enables more flexibility and possibility 
of scale-up.  
CFPS can be used to enable both CPP and CPP-cargo fusion production in a 
test tube without host cells limitations. For peptide synthesis, the potential 
disadvantage is the stability and product yield. Due to the length of the peptides (< 3 
 
Figure 7.3 Schemes of cell-free protein (CFPS) synthesis systems for peptide/protein 
production. Reactions can be achieved in a test tube or can be scaled up by adding more 
cell extracts and essential components [7].  
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kDa), the synthesis efficiency could be substantially lower than protein synthesis, as 
CFPS are often used to produce full-size proteins. To solve the problem, I can design 
a longer PCR fragments with multiple CPP units, separated by enzyme-cleavage 
recognition sites. The long fragments can be further purified using a fast liquid 
chromatography system (FPLC) and cleaved by an enzyme to recover CPP units 
(Figure 7.4 A).  
 
 
Figure 7.4 Schemes of producing CPPs or CPP-Cargo fusion proteins using CFPS. (A) 
Multiple CPP subunits will be produced by PCR on one bigger DNA fragment, which will 
be used for CFPS reactions. The big peptide will be recovered by affinity purification, 
followed by on-column cleavage by adding protease into the resin. Isolated CPP units will 
be separated from the enzyme in the flow-through by size-exclusion chromatography 
(SEC) and the latter elution represent the smaller CPP elution. (B) Plasmid DNA encoding 
CPP-Cargo fusions will constructed by cloning in bacteria. Purified plasmid DNA will be 
added into the tube for CFPS reactions. Protein will be recovered by affinity purification 
and released from the column by cleavage. Protein of interests and enzyme can be 
separated by ion-exchange chromatography by the difference in isoelectric point (pI).  
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To produce CPP-cargo fusion proteins, I can use molecular cloning 
techniques, similar to those in Chapter 6, to construct new plasmid DNA containing 
template DNA that combines the CPP and cargo protein on the same plasmid (Figure 
7.4 B). Fusion proteins can be purified using FPLC, and the affinity tag can be 
removed by on-column purification methods. Additional work of CFPS system 
optimization and yield control will enable us to utilize this method to produce more 
peptides or fusion proteins. 
7.2.2. Non-natural amino acid (NAA) incorporation 
The toxicity of CPP-cargo fusions to the cells mainly comes from the peptides 
and no loss of cell viability is observed when I only express cargo proteins (GFP) in 
bacterial cells. An alternative to recombinantly producing fusions is to produce 
protein cargos alone recombinantly, have the CPP synthesized separately, and then 
perform peptide conjugation to the cargo in vitro.  
Non-natural amino acid incorporation has been widely used to produce 
proteins with non-natural amino acids to study protein folding [8] and photoswitching 
[9] and to allow protein labeling using click chemistry [10, 11]. Ivana et al. 
successfully used several non-natural amino acids with alkyne groups to allow the 
conjugation of a fluorescent dye with azide modification through click chemistry 
[10]. Alkyne-containing proteins have been produced via codon-suppression methods 
in E. coli, yeast, and mammalian cells [12-14]. The amber codon (UAG) is one of the 
most commonly used codons to allow NNA incorporation. In addition to the template 
DNA encoding the cargo proteins with a UAG codon, specific plasmids encoding 
amber tRNA and aminoacyl-tRNA synthetase (aaRS) need to be used to co-transfrom 
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the host cells. aaRS will aminoacylate the tRNA to only allow NAA transportation at 
the UAG site (Figure 7.5 [15]). In such a way, recombinant cargo proteins will allow 
bioconjugation to CPPs with an azide modification by click chemistry.  
NAA incorporation can also be performed in vitro via CFPS methods. Hong 
et al. used CFPS to incorporate NAAs into proteins using E. coli extracts [7]. 
Additional DNA encoding tRNA, aaRS will be added into the system on top of 
regular CPFS essential components. CFPS can resolve the potential toxicity due to 
overexpression of tRNA and aaRS. This work, along with cell-free synthesis of CPPs 
will enable complete biosynthesis and bioconjugation in vitro and allow a higher 
degree of freedom in choosing cargo proteins without limitations from the host cells.  
 
Figure 7.5 Schematic representation of NAAs incorporation via amber codon 
suppression. Plasmids encoding tRNA, aaRS, and the new protein synthesis DNA with 
amber codon need to be co-transformed.  aaRS will target the tRNA with NAA to the 
amber site on mRNA sequence to substitute the stop codon with a new amino acid with 
modified side chain, allowing downstream bioconjugation [15].  
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7.3. CPP-cargo fusion protein secretion 
As mentioned above, the potential toxicity from the CPPs is limiting the 
recombination expression and production of CPP-cargo fusion proteins in microbial 
cells. I have described the CPFS methods and NAA incorporation to allow the in vitro 
production of CPPs and CPP-cargo fusions to bypass the limitation from the host 
cells. Another method to reduce to cytotoxicity of the fusion proteins is to have the 
protein secreted after synthesis to prevent intracellular accumulation of toxic proteins.  
7.3.1. Bacterial secretion pathway for protein expression 
Most of E. coli secreted proteins are either translocated into the periplasmic 
space in soluble form or are anchored to the inner or outer membranes, with only a 
small portion of protein secreted into the extracellular space [16].  
The twin arginine translocation (Tat) pathway is a widely studied protein 
secretion pathway in E. coli. The Tat pathway is capable of translocating correctly 
folded protein across the inner membrane. It requires a conserved, distinctive signal 
peptide to allow the secretion and periplasmic localization [17]. The enzymes on the 
inner membrane not only regulate the anchoring and translocation process, but also 
act as the “quality control” unit for proper protein folding and even disulfide bond 
formation. Although it has been suggested that the Tat pathway is less efficient than 
the secretory pathway [18], the quality control mechanism still makes the Tat 
pathway a promising way to secrete soluble recombinant proteins, which can be used 
to produce correctly folded CPP-cargo fusion proteins.  
Instead of translocating proteins into the periplasm, secreting proteins into the 
growth medium can protect the proteins from being degraded by the intracellular 
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proteases and simplify downstream protein recovery and purification. Most of the 
outer membrane protein secretion is through non-specific pathways with 
compromised membrane permeability. Alternatively, Salmonella entertica has a Type 
III secretion mechanism to allow direct secretion via a membrane channel “needle”, 
bypassing the periplasm.  Metcalf et al. have shown stable protein expression and 
secretion via this Type III pathway, and they suggested that the needle can also act as 
a folding quality control mechanism to ensure the folding and the biological activity 
of the secreted proteins [19]. This method gives us an alternative way to produce CPP 
fusions and allow faster protein recovery.  
7.3.2. Yeast secretion pathway for protein expression 
Protein secretion in prokaryotic cells has several limitations including low 
secretion efficacy, missing folding quality control (in the secretory pathway), and 
lack of post translational modification (PTM). Secretory expression of heterologous 
proteins in eukaryotic cells such as yeast can allow correct folding and secretion of 
proteins with the help of the endoplasmic reticulum (ER) and Golgi, and, most 
importantly, the proteins can be glycosylated [20]. Several strains have been 
successfully engineered to allow high-efficiency recombinant protein secretion, 
including strains of Pichia pastoris, Hansenula polymorpha, Saccharomyces 
cerevisiae, and Schizosaccharomyces pombe. There are various expression systems 
with different promoters for protein expression, such as the inducible promoters 
ADH2 and SUC2 to allow controlled expression and constitutive promoters like 
GAPDH for continuous protein expression [21].  
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There are several challenges associated with yeast recombinant protein 
expression. The intracellular trafficking is difficult to control. Some of the secreted 
vesicles after the Golgi will be directed to vacuoles, significantly reducing 
extracellular protein concentration. The difficulty in controlling the degree of PTM 
also diversifies the protein properties. Compared with bacterial expression system, 
like T7, the overall protein expression level and yield in yeast is much lower than 
engineered bacterial strains. A high cell density fermentation is also important to 
increase the yield of production and extra experiments are needed for optimization. 
These limitations need to be further explored to enable better protein secretion in 
yeast cells.  
7.3.3. Mammalian secretion pathway for protein expression 
Although yeast cells can be engineered to enable robust protein over-
expression and high-yield cell culture, the divergence from native human PTM and 
variability in expression levels limit the application of yeast expression systems for 
some routine therapeutic protein production [22].  
Mammalian cell culture is promising for biopharmaceutical protein 
production. The protein folding, PTM, and secretion are more consistent compared 
with other expression system. There are well designed expression vectors such as 
CMV and SV40 to allow heterologous protein expression [23]. Various signal 
sequences allow stable protein production and secretion. Examples like interleukin-2, 
CD5, trypsinogen and prolactin are well described and show consistent protein 
secretion [24]. To ensure stable protein expression, a proper mammalian cell line is 
very important. One of the most commonly used engineering cell line is the Chinese 
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hamster ovary (CHO) cell line. CHO cells are widely used for monoclonal antibody 
and therapeutic protein production in the biopharmaceutical industry, and culturing of 
these cells can be scaled up to larger scale bioreactors. With these tools, I can explore 
the possibility to use mammalian cells to produce CPP-cargo protein fusions with less 
toxicity to host cells and more specificity toward fungal pathogens.  
7.4. Conclusion 
The work presented in this thesis allows more comprehensive understanding 
of the structure-function relationships of CPPs towards fungal pathogens. Antifungal 
agent conjugation to CPPs represents an application of using CPP to deliver drugs to 
combat fungal infections. Additional work on peptide/protein production will enable 
us to have a larger set of CPPs and CPP-cargo fusion proteins to enable future studies 
to understand the limitation on the types of cargos that can be delivered. CFPS 
methods will remove the limitation of cells in expression and allow high-yield in vitro 
CPP/CPP-cargo expression and conjugation. To help eliminate the potential 
cytotoxicity issue from the peptides inside production hosts, secretion expression 
systems with different types of cells should be widely studied. These studies will 
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